<SEC-DOCUMENT>0001096906-25-001839.txt : 20251114
<SEC-HEADER>0001096906-25-001839.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114141545
ACCESSION NUMBER:		0001096906-25-001839
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		42
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		251484458

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		8015215301

	MAIL ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20250930_10q.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://www.utahmed.com/20250930" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D250101_250930" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="D250101_250930" id="fact2">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D250101_250930" id="fact3">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="D250101_250930" id="fact4">2025</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="D250101_250930" id="fact5">Q3</ix:nonNumeric>
</ix:hidden>
<ix:references>
	<link:schemaRef xlink:type="simple" xlink:href="utmd-20250930.xsd"/>
</ix:references>
<ix:resources>
<i:unit id="USD">
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id="Shares">
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id="UsdPerShare">
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
<i:unit id="Pure">
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:context id="D250101_250930">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q3">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="I251110">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-11-10</i:instant>
</i:period>
</i:context>
<i:context id="E24">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q3">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q3">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240930">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="E23">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q3">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-09-30</i:instant>
</i:period>
</i:context>
<i:context id="D250101_250930_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q2">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-06-30</i:instant>
</i:period>
</i:context>
<i:context id="Y25Q3_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="E25Q3_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q3_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q3_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E25Q3_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2025-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q2_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-06-30</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q3_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q3_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q3_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q3_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q3_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q3_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q3_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E24Q3_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-09-30</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="D240101_240930_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240930_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240930_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D240101_240930_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-01-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y25Q3_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2025-07-01</i:startDate>
<i:endDate>2025-09-30</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q3_StScenario-SingleOperatingSeg">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-07-01</i:startDate>
<i:endDate>2024-09-30</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">UNITED STATES</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Washington, D.C. &#160;20549</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D250101_250930" escape="true" id="ixv-6827">10-Q</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="D250101_250930" format="ixt-sec:boolballotbox" id="ixv-6828">&#9746;</ix:nonNumeric> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D250101_250930" format="ixt:date-monthname-day-year-en" id="ixv-6829">September 30, 2025</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">OR</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="D250101_250930" format="ixt-sec:boolballotbox" id="ixv-6830">&#9744;</ix:nonNumeric> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Commission File No. <span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D250101_250930" escape="true" id="ixv-6831">001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D250101_250930" escape="true" id="ixv-6832">UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(Exact name of Registrant as specified in its charter)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D250101_250930" escape="true" id="ixv-6833">UT</ix:nonNumeric>AH</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D250101_250930" escape="true" id="ixv-6834">87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of incorporation or organization)</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D250101_250930" escape="true" id="ixv-6835">7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D250101_250930" escape="true" id="ixv-6836">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D250101_250930" format="ixt-sec:stateprovnameen" id="ixv-6837">Utah</ix:nonNumeric> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D250101_250930" escape="true" id="ixv-6838">84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="D250101_250930" escape="true" id="ixv-6839">801</ix:nonNumeric>) </span><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D250101_250930" escape="true" id="ixv-6840">566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Title of each class:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Trading Symbol:</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="D250101_250930" escape="true" id="ixv-6841">Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="D250101_250930" escape="true" id="ixv-6842">UTMD</ix:nonNumeric></p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="D250101_250930" id="ixv-6843">NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="D250101_250930" id="ixv-6844">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="D250101_250930" id="ixv-6845">Yes</ix:nonNumeric>&#160;<span style="font-family:Wingdings">x</span> &#160;&#160;No&#160;<span style="font-family:Wingdings">o</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Large accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Accelerated filer&#160;<span style="font-family:Wingdings">o</span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="D250101_250930" format="ixt-sec:entityfilercategoryen" id="ixv-6846">Non-accelerated filer</ix:nonNumeric> <span style="font-family:Wingdings">x</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="D250101_250930" format="ixt-sec:boolballotbox" id="ixv-6847">&#9746;</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D250101_250930" format="ixt-sec:boolballotbox" id="ixv-6848">&#9744;</ix:nonNumeric></p>
</td></tr>
</table>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Wingdings">o</span> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="D250101_250930" format="ixt-sec:boolballotbox" id="ixv-6849">&#9744;</ix:nonNumeric> &#160;&#160;No&#160;<span style="font-family:Wingdings">x</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of November 10, 2025: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I251110" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-6850">3,203,672</ix:nonFraction>.&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify"> &#160;</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">INDEX TO FORM 10-Q</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.74%;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">PAGE</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0">PART I - FINANCIAL INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a1" style="text-decoration:none">Item 1. Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Consolidated Condensed Balance Sheets as of </a><a href="#a2" style="text-decoration:none">September 30, 2025 and December 31, 2024</a> </span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a3" style="text-decoration:none">Consolidated Condensed Statements of Income for the </a><a href="#a3" style="text-decoration:none">t</a><a href="#a3" style="text-decoration:none">hree and </a><a href="#a3" style="text-decoration:none">n</a><a href="#a3" style="text-decoration:none">ine</a><a href="#a3" style="text-decoration:none"> months ended </a><a href="#a3" style="text-decoration:none">S</a><a href="#a3" style="text-decoration:none">eptember </a><a href="#a3" style="text-decoration:none">30</a><a href="#a3" style="text-decoration:none">, 2025 and </a><a href="#a3" style="text-decoration:none">S</a><a href="#a3" style="text-decoration:none">eptember 30</a><a href="#a3" style="text-decoration:none">, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">2</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Consolidated Condensed Statements of Cash Flows for the </a><a href="#a4" style="text-decoration:none">n</a><a href="#a4" style="text-decoration:none">ine</a><a href="#a4" style="text-decoration:none"> </a><a href="#a4" style="text-decoration:none">months ended </a><a href="#a4" style="text-decoration:none">S</a><a href="#a4" style="text-decoration:none">eptember </a><a href="#a4" style="text-decoration:none">30</a><a href="#a4" style="text-decoration:none">, 2025 and </a><a href="#a4" style="text-decoration:none">S</a><a href="#a4" style="text-decoration:none">eptember 30</a><a href="#a4" style="text-decoration:none">, 2024</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">3</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a5" style="text-decoration:none">Consolidated Condensed Statements of Stockholders&#8217; Equity for the </a><a href="#a5" style="text-decoration:none">t</a><a href="#a5" style="text-decoration:none">hree and </a><a href="#a5" style="text-decoration:none">n</a><a href="#a5" style="text-decoration:none">ine</a><a href="#a5" style="text-decoration:none"> </a><a href="#a5" style="text-decoration:none">months ended </a><a href="#a5" style="text-decoration:none">S</a><a href="#a5" style="text-decoration:none">eptember </a><a href="#a5" style="text-decoration:none">30</a><a href="#a5" style="text-decoration:none">, 2025 and </a><a href="#a5" style="text-decoration:none">S</a><a href="#a5" style="text-decoration:none">eptember 30</a><a href="#a5" style="text-decoration:none">, 2024</a></span> </p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">4</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-left:18pt;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a6" style="text-decoration:none">Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">5</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a7" style="text-decoration:none">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a8" style="text-decoration:none">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">18</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a9" style="text-decoration:none">Item 4. Controls and Procedures</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">18</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">PART II &#8211;&#160;OTHER INFORMATION</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Item 1. Legal Proceedings</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">19</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Item 1A. Risk Factors</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">19</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">19</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a13" style="text-decoration:none">Item 6. Exhibits</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td></tr>
<tr><td valign="bottom" style="width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt">&#160;</p>
</td><td valign="bottom" style="width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td valign="bottom" style="background-color:#D3F0FE;width:88.26%"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">SIGNATURES</a></span> </p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.74%"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<a id="a1"></a><a id="a2"></a><table style="border-collapse:collapse;width:468pt"><tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">PART I &#160;- &#160;FINANCIAL INFORMATION</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:10pt Times New Roman;margin:0"><b>Item 1. &#160;Financial Statements</b></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">SEPTEMBER 30, 2025 AND DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="7" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(audited)</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"> </td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">SEPTEMBER 30, 2025</span></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">DECEMBER 31, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">ASSETS</span></p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Current assets:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Cash &amp; investments</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6851">84,267</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6852">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Accounts &amp; other receivables, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6853">3,725</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6854">4,094</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6855">8,118</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6856">8,812</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Other current assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6857">422</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6858">448</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total current assets</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6859">96,532</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6860">96,330</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6861">10,000</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6862">9,763</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Goodwill</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6863">14,051</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6864">13,580</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6865">55,948</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6866">53,772</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:223.4pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets - accumulated amortization</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6867">54,556</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6868">50,907</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6869">1,392</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6870">2,865</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total assets</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6871">121,975</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:Assets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6872">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:201.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Current liabilities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6873">768</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6874">696</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6875">2,243</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6876">3,061</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total current liabilities</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6877">3,011</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6878">3,757</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Deferred tax liability - Femcare IIA</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6879">248</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6880">603</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Operating lease liability</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6881">241</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6882">282</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6883">223</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6884">469</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6885">3,723</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6886">5,111</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:201.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:10pt Times New Roman;margin:0">Stockholders' equity:</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-6pt;margin-left:6pt">Common stock - $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E25Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6887"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E24" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6888">0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6889"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6890">50,000</ix:nonFraction></ix:nonFraction> shares; issued - September 30, 2025, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6891"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6892">3,204</ix:nonFraction></ix:nonFraction> shares and December 31, 2024, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6893"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E24" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6894">3,335</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6895">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6896">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:223.4pt"><p style="font:10pt Times New Roman;margin:0">Accumulated other comprehensive income (loss)</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E25Q3" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6897">9,738</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E24" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6898">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Additional paid-in capital</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E25Q3" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6899">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E24" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6900">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:212.3pt"><p style="font:10pt Times New Roman;margin:0">Retained earnings</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6901">127,958</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6902">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total stockholders' equity</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6903">118,252</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6904">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:201.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:201.2pt"><p style="font:10pt Times New Roman;margin:0">Total liabilities and stockholders' equity</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:113.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:95pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6905">121,975</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:109.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:92pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6906">122,538</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:223.45pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:113.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:109.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a3"></a><table style="border-collapse:collapse;width:470.25pt"><tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:470.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:470.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:470.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="11" valign="bottom" style="width:470.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:139.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">THREE MONTHS ENDED</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:133.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">NINE MONTHS ENDED</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:139.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEPTEMBER 30,&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:133.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEPTEMBER 30,&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"/><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:64.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:58.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:60.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Sales, net</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6907">9,812</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6908">10,005</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6909">29,475</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6910">31,745</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Cost of goods sold</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6911">4,208</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6912">4,203</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6913">12,738</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6914">12,925</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:162.15pt"><p style="font:10pt Times New Roman;margin:0">Gross profit</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6915">5,604</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6916">5,802</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6917">16,737</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6918">18,820</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Operating expense</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:162.15pt"><p style="font:10pt Times New Roman;margin:0">Selling, general and administrative</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6919">2,826</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6920">2,287</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6921">7,320</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6922">7,464</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:162.15pt"><p style="font:10pt Times New Roman;margin:0">Research &amp; development</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6923">167</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6924">172</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6925">456</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6926">692</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:145.4pt"><p style="font:10pt Times New Roman;margin:0">Total operating expense</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6927">2,993</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6928">2,459</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6929">7,776</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6930">8,156</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:162.15pt"><p style="font:10pt Times New Roman;margin:0">Operating income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6931">2,611</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6932">3,343</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6933">8,961</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6934">10,664</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Other income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6935">698</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6936">836</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6937">2,043</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6938">2,524</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:162.15pt"><p style="font:10pt Times New Roman;margin:0">Income before provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6939">3,309</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6940">4,179</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6941">11,004</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6942">13,188</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6943">678</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6944">616</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6945">2,284</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6946">2,216</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6947">2,631</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6948">3,563</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6949">8,720</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6950">10,972</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (basic)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6951">0.82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6952">1.02</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D250101_250930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6953">2.68</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6954">3.10</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (diluted)</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6955">0.82</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6956">1.02</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D250101_250930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6957">2.68</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-6958">3.10</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0"> Shares outstanding - basic</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6959">3,207</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6960">3,478</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D250101_250930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6961">3,254</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6962">3,542</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding - diluted</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6963">3,207</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6964">3,478</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D250101_250930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6965">3,254</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-6966">3,542</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="3" valign="bottom" style="width:173.95pt"><p style="font:10pt Times New Roman;margin:0">Other comprehensive income (loss):</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:162.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-9.75pt;margin-left:9.75pt">Foreign currency translation net of taxes of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y25Q3" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6967"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q3" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6968"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D250101_250930" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6969"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="D240101_240930" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-6970">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:61.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6971">376</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:64.25pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6972">1,432</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:58.95pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6973">2,170</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:60.75pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6974">769</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0">Total comprehensive income</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:61.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:44pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6975">2,255</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:46pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6976">4,995</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:58.95pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:6pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:42pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6977">10,890</ix:nonFraction></kbd>&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:60.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6978">11,741</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:16.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:145.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:61.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="5" valign="bottom" style="width:247.5pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:64.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:58.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:60.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</div>
<div style="margin-left:72pt"><a id="a4"></a><table style="border-collapse:collapse"><tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024</span></p>
</td></tr>
<tr style="height:7.2pt"><td colspan="8" valign="bottom" style="width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:182.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEPTEMBER 30,</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:238.1pt"/><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6979">8,720</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6980">10,972</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0">Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Depreciation</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6981">614</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6982">530</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6983">1,593</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6984">1,548</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Provision for (recovery of) losses on accounts receivable</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6985">395</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6986">6</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Amortization of right of use assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6987">41</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6988">38</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6989">641</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6990">417</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Stock-based compensation expense</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6991">262</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6992">184</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Tax benefit attributable to exercise of stock options</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D250101_250930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-6993">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6994">20</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0"> &#160;Changes in operating assets and liabilities:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:250.1pt"><p style="font:10pt Times New Roman;margin:0">Accounts receivable and other receivables</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6995">97</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-6996">306</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:250.1pt"><p style="font:10pt Times New Roman;margin:0">Inventories</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6997">1,009</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6998">508</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:250.1pt"><p style="font:10pt Times New Roman;margin:0">Prepaid expenses and other current assets</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-6999">52</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7000">54</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="background-color:#D3F0FE;width:250.1pt"><p style="font:10pt Times New Roman;margin:0">Accounts payable</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7001">69</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7002">229</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="2" valign="bottom" style="width:250.1pt"><p style="font:10pt Times New Roman;margin:0">Accrued expenses</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7003">802</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7004">1,460</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0">Total adjustments</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7005">2,495</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7006">922</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:238.1pt"><p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7007">11,215</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7008">11,894</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0">Capital expenditures for:</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7009">262</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7010">221</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Intangible assets</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D250101_250930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7011">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7012">5</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from sale of:</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D250101_250930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7013">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7014">27</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:238.1pt"><p style="font:10pt Times New Roman;margin:0">Net cash used in investing activities</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7015">262</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7016">199</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from issuance of common stock - options</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D250101_250930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7017">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7018">390</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7019">7,361</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7020">13,259</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="background-color:#D3F0FE;width:274pt"><p style="font:10pt Times New Roman;margin:0">Payment of dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7021">3,006</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7022">3,222</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:238.1pt"><p style="font:10pt Times New Roman;margin:0">Net cash used in financing activities</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7023">10,367</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7024">16,091</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Effect of exchange rate changes on cash</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7025">705</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7026">20</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Net increase/(decrease) in cash and cash equivalents</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7027">1,291</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7028">4,416</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Cash at beginning of period</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7029">82,976</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7030">92,868</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:10pt Times New Roman;margin:0">Cash at end of period</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7031">84,267</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7032">88,452</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="5" valign="bottom" style="width:285.95pt"><p style="font:10pt Times New Roman;margin:0">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="background-color:#D3F0FE;width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for income taxes</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7033">2,852</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7034">3,713</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:262.1pt"><p style="font:10pt Times New Roman;margin:0">Cash paid during the period for interest</p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:65pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="D250101_250930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7035">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:59pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="D240101_240930" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7036">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:11.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:238.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:11.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:83.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:22.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="4" valign="bottom" style="width:274pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:11.95pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:83.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:22.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:45pt;width:693pt"><a id="a5"></a><table style="border-collapse:collapse;width:100%"><tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Three and Nine Months Ended September 30, 2025 and 2024</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="12" valign="bottom" style="width:100%"><p style="font:8pt Times New Roman;margin:0;text-align:center">(In thousands - unaudited)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Accumulated</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Additional</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Other</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:19.66%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Common Stock</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Paid-in</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Comprehensive</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Retained</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0;text-align:center">Stockholders'</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"/><td valign="bottom" style="width:8.8%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Shares</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.78%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Amount</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:10.82%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Capital</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:14.9%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Income</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:8.78%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Earnings</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:12.88%;border-bottom:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0;text-align:center">Equity</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at June 30, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7037">3,216</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7038">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7039">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7040">9,362</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7041">126,862</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7042">117,533</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7043">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7044">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7045">95</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7046">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7047">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7048">95</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7049">12</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7050">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7051">95</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7052">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7053">558</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y25Q3" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7054">653</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7055">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7056">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7057">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7058">376</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7059">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y25Q3" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7060">376</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7061">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7062">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7063">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7064">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7065">977</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7066">977</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:12.15pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7067">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7068">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7069">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7070">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7071">2,631</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7072">2,631</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at September 30, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7073">3,204</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7074">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7075">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7076">9,738</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7077">127,958</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7078">118,252</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at December 31, 2024</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7079">3,335</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7080">33</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7081">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7082">11,908</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7083">129,302</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7084">117,427</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7085">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7086">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7087">262</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7088">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7089">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7090">262</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7091">131</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7092">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D250101_250930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7093">262</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D250101_250930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7094">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D250101_250930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7095">7,098</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D250101_250930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7096">7,361</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7097">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7098">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7099">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7100">2,170</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7101">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7102">2,170</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7103">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7104">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7105">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7106">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7107">2,966</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7108">2,966</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7109">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7110">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7111">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7112">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7113">8,720</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7114">8,720</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at September 30, 2025</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E25Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7115">3,204</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7116">32</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7117">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7118">9,738</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7119">127,958</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7120">118,252</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at June 30, 2024</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7121">3,499</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7122">35</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7123">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7124">11,322</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7125">135,339</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q2" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7126">124,052</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7127">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7128">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7129">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7130">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7131">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="Y24Q3" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7132">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7133">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7134">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7135">53</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7136">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7137">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7138">53</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7139">58</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7140">1</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7141">53</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7142">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7143">3,812</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q3" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7144">3,866</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7145">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7146">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7147">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7148">1,432</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7149">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7150">1,432</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7151">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7152">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7153">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7154">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7155">1,038</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7156">1,038</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7157">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7158">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7159">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7160">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7161">3,563</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7162">3,563</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at September 30, 2024</p>
</td><td valign="middle" style="width:8.8%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7163">3,441</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7164">34</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7165">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.9%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7166">9,890</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7167">134,053</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7168">124,197</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at December 31, 2023</p>
</td><td valign="middle" style="width:8.8%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7169">3,630</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7170">36</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:10.82%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7171">593</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:14.9%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7172">10,658</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:8.78%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7173">138,341</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:12.88%;border-top:0.5pt solid #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7174">128,313</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7175">8</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7176">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7177">390</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7178">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7179">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7180">390</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Stock option compensation expense</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7181">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7182">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7183">184</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7184">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7185">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7186">184</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7187">197</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7188">2</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7189">1,168</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7190">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7191">12,090</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240101_240930" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7192">13,259</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Foreign currency translation adjustment</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7193">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7194">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7195">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7196">769</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7197">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7198">769</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Common stock dividends</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7199">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7200">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7201">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7202">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7203">3,171</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#D3F0FE;width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7204">3,171</ix:nonFraction>)</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="bottom" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7205">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7206">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7207">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7208">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7209">10,972</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7210">10,972</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:24.64%"><p style="font:8pt Times New Roman;margin:0">Balance at September 30, 2024</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.8%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q3_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7211">3,441</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7212">34</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:10.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:57pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-7213">-</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:14.9%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:85pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7214">9,890</ix:nonFraction>)</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:8.78%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:43pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7215">134,053</ix:nonFraction>&#160;</kbd>&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:12.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:8pt Times New Roman;margin:0"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:8pt Times New Roman;width:71pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="E24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7216">124,197</ix:nonFraction>&#160;</kbd>&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:24.64%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:8.8%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td colspan="2" valign="bottom" style="width:33.44%"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:10.82%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:14.9%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:8.78%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:2.08%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:12.88%"><p style="font:8pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<a id="a6"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="D250101_250930" escape="true" id="ixv-3673"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(1)</kbd><kbd style="margin-left:19.8pt"></kbd>The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="D250101_250930" escape="true" id="ixv-3678"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c1" id="ixv-3685"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at September 30, 2025, and December 31, 2024, consisted of the following:&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c2" id="ixv-3689"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c1" continuedAt="c3"><ix:continuation id="c2" continuedAt="c4"><table style="border-collapse:collapse"><tr><td valign="top" style="width:141.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:97.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:93.6pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr><td valign="top" style="width:141.6pt"/><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:97.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:93.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:141.6pt"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:97.35pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7217">1,224</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:93.6pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7218">1,913</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:141.6pt"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:97.35pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7219">1,606</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:93.6pt"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7220">1,414</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:141.6pt"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td valign="top" style="background-color:#D3F0FE;width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:97.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7221">5,288</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:93.6pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7222">5,485</ix:nonFraction></kbd>&#160;</p>
</td></tr>
<tr><td valign="top" style="width:141.6pt"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td valign="top" style="width:60.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:97.35pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7223">8,118</ix:nonFraction></kbd>&#160;</p>
</td><td valign="top" style="width:11.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:93.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7224">8,812</ix:nonFraction></kbd>&#160;</p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c3"><ix:continuation id="c4"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="D250101_250930" escape="true" id="ixv-3774"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation. At September 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2025, and 2024, the Company recognized $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7227">95</ix:nonFraction> and $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7228">53</ix:nonFraction>, respectively, in stock-based compensation cost. &#160;In the nine months ended September 30, 2025, and 2024, the Company recognized $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7229">262</ix:nonFraction> and $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7230">184</ix:nonFraction>, respectively, in stock-based compensation cost.&#160;</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ProductWarrantyDisclosureTextBlock" contextRef="D250101_250930" escape="true" id="ixv-3780"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024, or September 30, 2025. </p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c5" id="ixv-3790"><p style="font:10pt Times New Roman;margin:0">(6) Global 3Q 2025 revenues (USD) by product category:</p>
<ix:nonNumeric name="fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c6" id="ixv-3792"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c5" continuedAt="c7"><ix:continuation id="c6" continuedAt="c8"><table style="border-collapse:collapse"><tr><td valign="top" style="width:184.5pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7231">869</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7232">170</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7233">1,039</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7234">2,521</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7235">2,433</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7236">4,954</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7237">1,622</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7238">554</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7239">2,176</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:184.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessorie</span>s*</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7240">847</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7241">796</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7242">1,643</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total:</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7243">5,859</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7244">3,953</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7245">9,812</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c7" continuedAt="c9"><ix:continuation id="c8" continuedAt="c10"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2025 revenues (USD) by product category:</p>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt"><ix:continuation id="c9" continuedAt="c11"><ix:continuation id="c10" continuedAt="c12"><table style="border-collapse:collapse"><tr><td valign="top" style="width:184.5pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7246">2,519</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7247">570</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7248">3,089</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7249">7,272</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7250">7,384</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7251">14,656</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7252">4,981</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7253">1,280</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7254">6,261</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:184.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessories*</span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7255">2,536</ix:nonFraction></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7256">2,933</ix:nonFraction></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:43.85pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7257">5,469</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:184.5pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0">:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7258">17,308</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7259">12,167</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7260">29,475</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c11"><ix:continuation id="c12"></ix:continuation><p style="font:10pt Times New Roman;margin:0">*includes assemblies and molded components sold to OEM customers. </p>
</ix:continuation><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c13" id="ixv-4071"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3<span style="vertical-align:super">rd</span> quarter 2025.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <i>(in thousands)</i>:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c14" id="ixv-4076"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
</ix:nonNumeric></ix:nonNumeric></div>
<div style="margin-left:72pt"><ix:continuation id="c13" continuedAt="c15"><ix:continuation id="c14" continuedAt="c16"><table style="border-collapse:collapse"><tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:131.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:153pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:131.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" valign="top" style="width:153pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"/><td valign="middle" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td valign="top" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td valign="top" style="background-color:#D3F0FE;width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7262">2,631</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7263">3,563</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D250101_250930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7264">8,720</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D240101_240930" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7265">10,972</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td valign="top" style="background-color:#D3F0FE;width:149.4pt"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td valign="top" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td valign="middle" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7266">3,207</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7267">3,478</ix:nonFraction></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D250101_250930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7268">3,254</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D240101_240930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7269">3,542</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y25Q3" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7270">-</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y24Q3" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7271">-</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D250101_250930" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7272">-</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D240101_240930" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-7273">-</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td valign="middle" style="width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y25Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7274">3,207</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q3" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7275">3,478</ix:nonFraction></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D250101_250930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7276">3,254</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D240101_240930" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-7277">3,542</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:149.4pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td valign="middle" style="width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y25Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7278">0.82</ix:nonFraction></p>
</td><td valign="top" style="width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7279">1.02</ix:nonFraction></p>
</td><td valign="top" style="width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D250101_250930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7280">2.68</ix:nonFraction></p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D240101_240930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7281">3.10</ix:nonFraction></p>
</td></tr>
<tr style="height:12.5pt"><td valign="top" style="background-color:#D3F0FE;width:149.4pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:53.45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y25Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7282">0.82</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:15.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q3" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7283">1.02</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:18pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:72pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D250101_250930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7284">2.68</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:67.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D240101_240930" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-7285">3.10</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c15"><ix:continuation id="c16"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0;color:#000000"> &#160;</p>
<ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c17" id="ixv-4294"><p style="font:10pt Times New Roman;margin:0">(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">6</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<ix:continuation id="c17" continuedAt="c18"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended September 30, 2025 and September 30, 2024:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="D250101_250930" escape="true" continuedAt="c19" id="ixv-4304"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</ix:nonNumeric></ix:continuation></div>
<div style="margin-left:72pt"><ix:continuation id="c18" continuedAt="c20"><ix:continuation id="c19" continuedAt="c21"><table style="border-collapse:collapse"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended September 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"/><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7288">9,812</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7289">10,005</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7290">3,359</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:StandardCostOfSales" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7291">3,456</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7292">849</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OtherCostOfSales" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7293">747</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7294">5,604</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7295">5,802</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7296">57.1</ix:nonFraction>%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:GrossProfitMargin" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7297">58.0</ix:nonFraction>%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7298">516</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7299">437</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7300">167</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7301">171</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:LitigationExpense" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7302">384</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:LitigationExpense" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7303">426</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7304">544</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7305">525</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7306">1,382</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7307">900</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7308">2,611</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7309">3,343</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7310">26.6</ix:nonFraction>%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="fil:OperatingIncomeMargin" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="INF" unitRef="Pure" scale="-2" format="ixt:num-dot-decimal" id="ixv-7311">33.4</ix:nonFraction>%</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7312">719</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherInterestAndDividendIncome" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7313">872</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td valign="top" style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7314">21</ix:nonFraction>)</p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-7315">36</ix:nonFraction>)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td valign="top" style="border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7316">3,309</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7317">4,179</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="top" style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7318">678</ix:nonFraction></p>
</td><td valign="top" style="background-color:#D3F0FE"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7319">615</ix:nonFraction></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td valign="top" style="border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y25Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7320">2,631</ix:nonFraction></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q3_StScenario-SingleOperatingSeg" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-7321">3,564</ix:nonFraction></p>
</td></tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="margin-left:72pt;width:468pt"><ix:continuation id="c20"><ix:continuation id="c21"></ix:continuation></ix:continuation><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="D250101_250930" escape="true" id="ixv-4508"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements. After September 30, 2025 through November 10, 2025, the Company made additional repurchases of 500 shares of its stock in the open market for $29, at a price of $57.90 per share.</p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a7"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">General</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2024, provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.  </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; A$ or AUD = Australia Dollars; &#163; or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Analysis of Results of Operations</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">a)</kbd><kbd style="margin-left:24.3pt"></kbd>Overview&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income statement results in 3Q and 9M 2025 compared to the same periods of 2024 were as follows:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:481.05pt;margin-left:3.4pt"><tr><td valign="top" style="width:146pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td><td valign="top" style="width:47.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td><td valign="top" style="width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:146pt"><p style="font:10pt Times New Roman;margin:0">Net Sales</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 9,812</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$10,005</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-indent:-4.5pt;text-align:right"> &#160;&#160;&#160;( 1.9%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 29,475</p>
</td><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$31,745</p>
</td><td valign="top" style="background-color:#D3F0FE;width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> ( 7.2%)</p>
</td></tr>
<tr><td valign="top" style="width:146pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,604</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,802</p>
</td><td valign="top" style="width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> ( 3.4%)</p>
</td><td valign="top" style="width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,737</p>
</td><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">18,820</p>
</td><td valign="top" style="width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> (11.1%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:146pt"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,611</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,343</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (21.9%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,961</p>
</td><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,664</p>
</td><td valign="top" style="background-color:#D3F0FE;width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> (16.0%)</p>
</td></tr>
<tr><td valign="top" style="width:146pt"><p style="font:10pt Times New Roman;margin:0">Income Before Tax</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,309</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,179</p>
</td><td valign="top" style="width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (20.8%)</p>
</td><td valign="top" style="width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,004</p>
</td><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,189</p>
</td><td valign="top" style="width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> &#160;(16.6%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:146pt"><p style="font:10pt Times New Roman;margin:0">Net Income (NI)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,631</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,564</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (26.2%)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,720</p>
</td><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,972</p>
</td><td valign="top" style="background-color:#D3F0FE;width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> (20.5%)</p>
</td></tr>
<tr><td valign="top" style="width:146pt"><p style="font:10pt Times New Roman;margin:0">Earnings per Diluted Share (EPS)</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.820</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.025</p>
</td><td valign="top" style="width:49.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (19.9%)</p>
</td><td valign="top" style="width:47.7pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.680</p>
</td><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.098</p>
</td><td valign="top" style="width:70.45pt"><p style="font:10pt Times New Roman;margin:0;margin-left:7.5pt;margin-right:11.25pt;text-align:right"> (13.5%)</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s 3Q 2025 financial performance was unusually affected by foreign trade events: i.e., the cancellation or possible delay of &#8220;non-changeable/non-cancellable orders&#8221; by two outside the U.S. (OUS) distributors. &#160;Payment terms for these distributors in the past have been full payment prior to shipment of ordered devices in order to eliminate risk of uncollectible receivables. So, non-prepayment as a practical matter canceled or changed the previously agreed upon non-changeable/non-cancellable orders. &#160;As a result, UTMD lost $976 in 3Q 2025 shipments and $581 in 3Q 2025 revenues. The lower loss of revenues was due to a EUR 360 cancellation fee invoiced UTMD&#8217;s China distributor for Ireland finished goods, work-in-process and custom raw materials which cannot be used for other customers. &#160;However, since it appears that the China distributor&#8217;s silence may leave UTMD holding the bag on inventory produced and/or acquired in good faith to complete the cancelled 2025 annual order, in order to report financial results conservatively, UTMD reserved an additional $395 in 3Q 2025 bad debt expense (G&amp;A expense category) which reduced 3Q 2025 operating income by that amount. Although UTMD has enjoyed supplying its devices to the China distributor for more than two decades, if the cancellation fee is not paid, it is unlikely that there will be a future business relationship.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">In quick summary, an unexpected loss of $581 in revenues (which helped reduce Ireland&#8217;s gross profit margin by lower absorption of fixed manufacturing overhead expense), and an additional $395 reduction in operating income (from bad debt reserve) occurred in 3Q 2025.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">In total, Worldwide (WW) consolidated sales in 3Q 2025 were $193 lower than in 3Q 2024, and were 2,270 lower in year-to-date (9M) 2025 compared to 9M 2024. Sales to UTMD&#8217;s China distributor noted above were $395 (cancellation fee) in 3Q 2025 compared to $781 in 3Q 2024, and $2,054 in 9M 2025 compared to $2,368 in 9M 2024. &#160;The negative sales trend from UTMD&#8217;s previous major OEM customer, PendoTECH, continued in 3Q 2025 but has almost bottomed out. Sales to PendoTECH WW were $96 in 3Q 2025 compared to $290 in 3Q 2024, and $360 in 9M 2025 compared to $2,346 in 9M 2024. &#160;In other words, sales to those two customers were $581 lower in 3Q 2025 compared to 3Q 2024, and $2,300 lower in 9M 2025 compared to 9M 2024, exceeding the aggregate change in UTMD&#8217;s applicable period revenues. &#160;&#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Sales invoiced in foreign currencies represented 29% of total WW consolidated 3Q 2025 sales (when expressed in USD) and 30% of 9M 2025 total WW consolidated sales. Constant currency sales, U.S. dollar sales using the same foreign currency exchange (FX) rates as in the prior year&#8217;s same periods, were $114 higher in 3Q 2025 as a result of a stronger EUR and GBP compared to 3Q 2024, and $244 higher for 9M 2025. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">8</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Profit margins in 3Q and 9M 2025 compared to 3Q and 9M 2024 follow:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:488.6pt;margin-left:-1.7pt"><tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt">&#160;</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">3Q 2025 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jul &#8211;&#160;Sep)</span></p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center">3Q 2024</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jul &#8211;&#160;Sep)</span></p>
</td><td valign="top" style="width:63.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center">9M 2025</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Sep)</span></p>
</td><td valign="top" style="width:65.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center">9M 2024</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">(Jan &#8211;&#160;Sep)</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:232.1pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Gross Profit Margin (GP/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">57.1%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">58.0% </p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">56.8%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">59.3%</p>
</td></tr>
<tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Operating Income Margin (OI/ sales):</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">26.6%</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.4%</p>
</td><td valign="top" style="width:63.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">30.4%</p>
</td><td valign="top" style="width:65.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.6%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:232.1pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">EBT Margin (EBT/ sales):</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.7%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">41.8%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">37.3%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">41.5%</p>
</td></tr>
<tr><td valign="top" style="width:232.1pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Net Income Margin (NI/ sales):</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">26.8%</p>
</td><td valign="top" style="width:63.8pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">35.6%</p>
</td><td valign="top" style="width:63.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">29.6%</p>
</td><td valign="top" style="width:65.15pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.6%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">EBT = Income Before Taxes = (Operating Income + Non-Operating Income)</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">In 3Q and 9M 2025, UTMD&#8217;s GP Margin (GPM) was reduced by planned higher manufacturing overhead costs with lower absorption as a result of lower sales. </p>
<p style="font:10pt Times New Roman;margin:0">Compared to the prior year, Operating Income margins in 2025 declined as a result of a lower GPM combined with higher operating expenses and lower sales. &#160;Excluding litigation expenses and non-cash amortization expense for the amortization of identifiable intangible assets (IIA) resulting from UTMD&#8217;s 2011 purchase of Femcare, both of which are included in General &amp; Administrative (G&amp;A) expenses, the following table compares consolidated WW Operating Expenses for 3Q 2025 and 9M 2025 with the same periods in 2024:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;border:0.5pt solid #000000"><tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">WW Operating Expense*</span></p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Expense &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[000 $]</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$2,073</p>
</td><td valign="top" style="background-color:#D3F0FE;width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1,516</p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$5,226</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$4,821</p>
</td></tr>
<tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Percent of Revenues</p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">21.1%</p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">15.2%</p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">17.7%</p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">15.2%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt">*Excluding litigation expense and UK IIA amortization expense </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">The major difference in the table above was a $395 3Q 2025 charge to UTMD&#8217;s bad debt reserve for cancellation fees invoiced UTMD&#8217;s China distributor for cancelling a noncancellable order in 3Q 2025 for which UTMD had already incurred substantial costs. In addition, a stronger EUR and GBP, converting OUS subsidiary foreign currency operating expenses, added $28 to 3Q 2025 operating expenses and $68 to 9M 2025 operating expenses relative to what those expenses would have been using the 2024 periods&#8217; foreign currency exchange (FX) rates. </p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;border:0.5pt solid #000000"><tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Litigation Expense</span></p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Expense &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[000 $]</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 384</p>
</td><td valign="top" style="background-color:#D3F0FE;width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 426</p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 983</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1,813</p>
</td></tr>
<tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Percent of Revenues</p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">3.9%</p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">4.3%</p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">3.3%</p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">5.7%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;border:0.5pt solid #000000"><tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UK IIA Amort Expense</span></p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Expense &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[000 GBP]</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#163; 397</p>
</td><td valign="top" style="background-color:#D3F0FE;width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#163; 397</p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#163;1,192</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#163;1,192</p>
</td></tr>
<tr><td valign="top" style="width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Expense &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[000 &#160;$]</p>
</td><td valign="top" style="width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 536</p>
</td><td valign="top" style="width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 517</p>
</td><td valign="top" style="width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1,568</p>
</td><td valign="top" style="width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1,522</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:126.9pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Percent of Revenues</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">5.5%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:79.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">5.2%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:73.5pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">5.3%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:81pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">4.8%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The same GBP IIA amortization expenses in both years&#8217; periods, but a greater dilution in the 2025 periods&#8217; Operating Income margin due to a stronger GBP and lower revenues.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">EBT in 2025 compared to 2024 was lower because of the lower Operating Income combined with lower Non-operating Income. With lower interest rates on lower cash balances due to share repurchases in 2025, non-operating income was $698 in 3Q 2025 compared to $836 in 3Q 2024, and $2,043 in 9M 2025 compared to $2,524 in 9M 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Net Income margins were further reduced by higher income tax provision rates in 2025 relative to 2024. Earnings Per Share (EPS) in 3Q 2025 were only 20% lower than in 3Q 2024 when Net Income was 26% lower, and only 13% lower in 9M 2025 than in 9M 2024 when Net Income was 21% lower, due to share repurchases. Additional income statement details are provided later in this report. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s September 30, 2025 Balance Sheet was stronger than at the end of 2024 with a higher current ratio, lower total liabilities and higher stockholders&#8217; equity, despite the lower sales and earnings, 9M 2025 cash payments of $3,006 in dividends to stockholders and use of $7,361 to repurchase UTMD shares. The 3Q 2025 ending share price increased $1.50 (+2.4%) from the end of 2024. &#160;&#160;&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">9</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2025 compared to the end of calendar year 2024 and the end of 3Q 2024 follow:</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9-30-25</span></p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">12-31-24</span></p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:16pt;text-align:right"><span style="border-bottom:1px solid #000000">Change</span></p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9-30-24</span></p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:78.6pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.34420</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.25209</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:16pt;text-align:right">7.4%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.33958</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> 0.3%</p>
</td></tr>
<tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.17331</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.03505</p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:16pt;text-align:right"> 13.4%</p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.11429</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> 5.3%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:78.6pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.66127</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.61834</p>
</td><td valign="top" style="background-color:#D3F0FE;width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:16pt;text-align:right">6.9%</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.69312</p>
</td><td valign="top" style="background-color:#D3F0FE;width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> (4.6%)</p>
</td></tr>
<tr><td valign="top" style="width:78.6pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:52.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.71789</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.69428</p>
</td><td valign="top" style="width:67.5pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:16pt;text-align:right">3.4%</p>
</td><td valign="top" style="width:58.5pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.73987</p>
</td><td valign="top" style="width:76.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> (3.0%)</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">b)</kbd><kbd style="margin-left:24.3pt"></kbd>Revenues (sales)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;For the U.S., Ireland, UK, France, Canada, Australia and New Zealand, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. About 14% of UTMD&#8217;s domestic end user sales, excluding Filshie device sales, go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. &#160;UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same for customers in the U.S. and outside the U.S. (OUS).</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year or less. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">Total WW UTMD consolidated <b>3Q 2025 sales</b> were $193 (1.9%) lower than in 3Q 2024. WW constant currency sales were $307 (3.1%) lower. U.S. domestic sales were 3.0% higher (without any FX impact), and outside the U.S. (OUS) sales were 8.5% lower. Without the benefit of a weaker USD in converting foreign currency sales, 3Q 2025 OUS sales were 11.1% lower. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic U.S. sales in 3Q 2025 were $172 higher at $5,859 compared to $5,687 in 3Q 2024 despite the $194 lower domestic sales to PendoTech. &#160;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and acquisition history. Domestic direct other device sales, representing 69% of total domestic sales, were $290 (+7.7%) higher in 3Q 2025 than in 3Q 2024. Domestic OEM sales, representing 11% of total domestic sales, were $285 (31.0%) lower, including the offsetting $194 lower PendoTECH OEM sales. Direct Filshie device sales, representing 20% of total domestic sales, were $169 (+16.5%) higher in 3Q 2025 compared to 3Q 2024. About half the increase in domestic Filshie sales was due to a 3Q 2025 price increase which was caused by U.S. tariffs. &#160;Filshie devices are manufactured in UTMD&#8217;s Ireland subsidiary and sold &#8220;intercompany&#8221;. &#160;Prices on intercompany sales are set by comparable third-party sales, i.e. OUS distributors, in order to satisfy taxing authorities. &#160;But intercompany sales are eliminated when UTMD sales are consolidated. &#160;Unfortunately, the U.S. government has recently set a 15% tariff on medical device imports from Ireland, which is a &#8220;top-line&#8221; excise tax on intercompany sales to the U.S. from UTMD&#8217;s Ireland subsidiary, which substantially increases consolidated expenses without any impact on sales. With the resulting approximate 50% decline in UTMD&#8217;s U.S. Filshie distributor margin, the Company had to increase its prices to U.S. medical facilities, which undoubtedly will be passed to patients, proving the unfavorable inflationary impact of tariffs on the regular private sector U.S. public. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">OUS sales in 3Q 2025 were 8.5% lower at $3,953 compared to $4,318 in 3Q 2024. The decrease in USD-denominated OUS sales was mitigated as a result of a weaker USD relative to the EUR and GBP, which added $114 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies in constant currency terms. FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 3Q 2025 and 3Q 2024 for revenue purposes follow:</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">10</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">3Q 2024</span> &#160;&#160;&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 1.3485</p>
</td><td valign="top" style="background-color:#D3F0FE;width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 1.3009</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">+ 3.7%</p>
</td></tr>
<tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 1.1748</p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 1.1091</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">+ 5.9%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 0.6548</p>
</td><td valign="top" style="background-color:#D3F0FE;width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 0.6687</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">( &#160;2.1%)</p>
</td></tr>
<tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 0.7256</p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 0.7339</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">( &#160;1.1%)</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The weighted average favorable FX rate difference impact on 3Q 2025 foreign currency OUS sales was 4.2%, increasing reported USD sales by $114 relative to the same foreign currency sales in 3Q 2024. &#160;In constant currency terms, foreign currency sales in 3Q 2025 were 21.7% lower than in 3Q 2024. The portion of OUS sales invoiced in foreign currencies in USD terms were 28.7% of total consolidated 3Q 2025 sales compared to 34.5% in 3Q 2024. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. Export sales from the U.S. to OUS distributors are invoiced in USD. &#160;Direct to end-user foreign currency OUS 3Q 2025 sales in USD terms were 6.7% higher in Ireland, 16.3% lower in Canada, 30.5% lower in France, 18.7% lower in AUS/NZ and 0.1% higher in the UK than in 3Q 2024. Aggregate sales to OUS distributors were $225 (8.3%) lower in 3Q 2025 than in 3Q 2024. &#160;This included the two OUS distributors which postponed or cancelled $581 in non-changeable/ noncancellable shipments. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">Total consolidated <b>9M 2025</b> UTMD WW consolidated sales were $2,271 (7.2%) lower than in 9M 2024. Constant currency 9M 2025 sales were helped $244 (+0.8%) due to a generally weaker USD year-to-date. U.S. domestic sales were 2.3% lower and OUS sales were 13.3% lower. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic U.S. sales in 9M 2025 were $17,308 compared to $17,709 in 9M 2024. &#160;Direct other device sales, representing 69% of total domestic sales, were $1,072 (+9.8%) higher in 9M 2025 than in 9M 2024. Domestic OEM sales, representing 11% of total domestic sales, were $1,706 (46.3%) lower. The PendoTECH portion of domestic OEM sales were $1,985 (84.6%) lower. In other words, 9M 2025 non-PendoTECH OEM sales were $279 higher. Direct domestic Filshie device sales, representing 19% of total domestic sales, were $233 (+7.5%) higher in 9M 2025 compared to 9M 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">OUS sales in 9M 2025 were 13.3% lower at $12,167 compared to $14,036 in 9M 2024. The decrease in 9M 2025 USD-denominated OUS sales was mitigated as a result of a weaker USD relative to the GBP and EUR which added a net $244 to OUS sales (constant currency terms) after the offsetting negative impact of a weaker AUD and CAD. &#160;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2025 and 9M 2024 for revenue purposes follow:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">9M 2024</span> &#160;&#160;&#160;</p>
</td><td valign="top" style="width:55.15pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 1.3145</p>
</td><td valign="top" style="background-color:#D3F0FE;width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 1.2760</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.15pt"><p style="font:10pt Times New Roman;margin:0">+ 3.0%</p>
</td></tr>
<tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 1.1333</p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 1.0886</p>
</td><td valign="top" style="width:55.15pt"><p style="font:10pt Times New Roman;margin:0">+ 4.1%</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#D3F0FE;width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 0.6396</p>
</td><td valign="top" style="background-color:#D3F0FE;width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 0.6617</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.15pt"><p style="font:10pt Times New Roman;margin:0">( &#160;3.3%)</p>
</td></tr>
<tr><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:13.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.1pt"><p style="font:10pt Times New Roman;margin:0"> 0.7144</p>
</td><td valign="top" style="width:75.9pt"><p style="font:10pt Times New Roman;margin:0"> 0.7355</p>
</td><td valign="top" style="width:55.15pt"><p style="font:10pt Times New Roman;margin:0">( &#160;2.9%)</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The weighted-average favorable impact on 9M 2025 WW consolidated sales was 0.8%, increasing reported USD sales by $244 compared to using the same foreign currency exchange rates as in 9M 2024. In constant currency terms, OUS sales in 9M 2025 were 15.1% lower than in 9M 2024. The portion of OUS sales invoiced in foreign currencies in USD terms was 30.0% of total consolidated 9M 2025 sales compared to 33.5% in 9M 2024. Direct to end-user foreign currency OUS 9M 2025 sales in USD terms were 17.2% lower in Ireland, 20.4% lower in Canada, 24.0% lower in France, 4.5% lower in the UK and 20.0% lower in AUS/NZ. Sales to OUS distributors/OEM customers were 13.6% lower in 9M 2025 than in 9M 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The 2025 decline in PendoTech OEM sales has been as expected in projections at the beginning of the year (about $2.3 million lower for the year). But with the unexpected distributor cancellations experienced in 3Q 2025 and generally weaker OUS economic conditions, management now expects that total annual 2025 consolidated sales may be about 7% lower compared to 2024, instead of the beginning of year 5% projection. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:-6.5pt">UTMD segments sales into the following general product categories: &#160;gynecology/ electrosurgery, labor &amp; delivery, neonatal critical care, and miscellaneous including blood pressure monitoring kits and accessories as well as related OEM products. &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">In 3Q 2025 compared to 3Q 2024, WW gynecology/ electrosurgery sales were 3% lower, WW neonatal device sales were 27% higher, WW labor &amp; delivery device sales were 1% lower and WW blood pressure monitoring and related OEM product sales were 23% lower. &#160;In 9M 2025 compared to 9M 2024, WW gynecology/ electrosurgery device sales were 8% lower, WW labor &amp; delivery device sales were about the same, WW neonatal device sales were 28% higher and WW blood pressure monitoring and related OEM product sales were 29% lower. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">11</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table provides USD sales amounts divided into general product categories for total sales and the subset of OUS sales:</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><span style="border-bottom:1px solid #000000">Global revenues by product category</span>:</p>
<table style="border-collapse:collapse;width:432pt;margin-left:0.9pt"><tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,039</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> $ 1,053</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,089</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,097</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,954</p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,093</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">14,656</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,005</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,176</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,713</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,261</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,901</p>
</td></tr>
<tr><td valign="top" style="width:207pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1,643</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">2,146</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">5,468</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">7,742</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;9,812</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$10,005</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$29,474</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$31,745</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">OUS revenues by product category</span>:</p>
<table style="border-collapse:collapse;width:432.2pt;margin-left:0.9pt"><tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;170</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;159</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;570</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;547</p>
</td></tr>
<tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,433</p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,795</p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,384</p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,945</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">554</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">342</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,280</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,053</p>
</td></tr>
<tr><td valign="top" style="width:207.2pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160;796</span></p>
</td><td valign="top" style="width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160;1,022</span></p>
</td><td valign="top" style="width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;2,932</span></p>
</td><td valign="top" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;3,491</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:207.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Total:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:58.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,953</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 4,318</p>
</td><td valign="top" style="background-color:#D3F0FE;width:63pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$12,166</p>
</td><td valign="top" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$14,036</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:24.3pt"></kbd>*includes assemblies and molded components sold to OEM customers.&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">c)</kbd><kbd style="margin-left:24.3pt"></kbd>Gross Profit&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Gross Profit results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers from revenues. UTMD&#8217;s Gross Profit was $198 (3.4%) lower in 3Q 2025 than in 3Q 2024, and $2,083 (11.1%) lower in 9M 2025 than in 9M 2024. Manufacturing costs include U.S. tariffs on imported components which were $78 in 3Q 2025, mostly due to importing Filshie devices from UTMD Ireland, compared to zero in 3Q 2024. &#160;Tariffs in 9M 2025 were $94 compared to $15 in 9M 2024. &#160;Those amounts do not include price increases on components purchased from U.S. suppliers due to tariffs that they have to pay. &#160;Given the Company&#8217;s strategy of vertical integration in a complex medical device industry, the relatively fixed manufacturing overhead costs of retaining critical management, engineering and quality assurance capabilities dominates the other more variable manufacturing costs of direct labor and materials. &#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:10.8pt">d)</kbd><kbd style="margin-left:22.5pt"></kbd>Operating Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income results from subtracting Operating Expenses from Gross Profit. &#160;Operating Income in 3Q 2025 was $2,611 compared to $3,343 in 3Q 2024, a 21.9% decline; and was $8,961 in 9M 2025 compared to $10,664 in 9M 2024, a 16.0% decline. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Operating Expenses are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes Operating Expenses in 3Q and 9M 2025 compared to the same periods in 2024 by Operating Expense (OE) category:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="bottom" style="width:59.4pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">OE<br/><span style="border-bottom:1px solid #000000">Category</span></p>
</td><td valign="bottom" style="width:54pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">3Q<br/><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="bottom" style="width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">3Q<br/><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="bottom" style="width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">9M<br/><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="bottom" style="width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="bottom" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">9M<br/><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="bottom" style="width:52.4pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 516</p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;5.3</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 437</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;4.4</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 1,540</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;5.2</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">$ 1,395</p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;4.4</p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A:</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2,310</p>
</td><td valign="top" style="width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">23.5</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">1,850</p>
</td><td valign="top" style="width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">18.5</p>
</td><td valign="top" style="width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;5,780</p>
</td><td valign="top" style="width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">19.6</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;&#160;6,069</p>
</td><td valign="top" style="width:52.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">19.1</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:59.4pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">R&amp;D:</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;&#160;167</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;1.7</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;&#160;172</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;1.7</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;457</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;1.6</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;692</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:52.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"> &#160;2.2</span></p>
</td></tr>
<tr><td valign="top" style="width:59.4pt"><p style="font:10pt Times New Roman;margin:0">Total OE:</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2,993</p>
</td><td valign="top" style="width:43.8pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">30.5</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2,459</p>
</td><td valign="top" style="width:52.4pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">24.6</p>
</td><td valign="top" style="width:52.4pt;border-left:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> 7,777</p>
</td><td valign="top" style="width:52.4pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">26.4</p>
</td><td valign="top" style="width:52.4pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> &#160;8,156</p>
</td><td valign="top" style="width:52.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">25.7</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Changes in foreign currency exchange (FX) rates had a small impact on consolidated financial results in 2025. The FX rate changes are noted in the revenues sections above. A stronger EUR and GBP, offset somewhat by a slightly weaker AUD and CAD in 3Q 2025 helped increase OUS S&amp;M expense by $3 and OUS G&amp;A expense by $25, of which $19 was from the same GBP amortization of Femcare IIA in 3Q 2025 and 3Q 2024. A stronger EUR and GBP offset by a weaker AUD and CAD in 9M 2025, increased OUS S&amp;M expenses by $4 and OUS G&amp;A expenses by $64, of which $46 was from the same GBP amortization of Femcare IIA in both 9M 2025 and 9M 2024. There were no OUS R&amp;D expenses. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">S&amp;M expenses in 3Q 2025 were up $79 mainly as a result of increased health plan expenses in the U.S. and higher fees charged by U.S. national distributors. S&amp;M expenses in 9M 2025 were $145 higher for the same reasons, plus as a result of a lower recovery of freight costs to customers. Headcount and salaries did not appreciably increase.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">R&amp;D expenses, only incurred in the U.S., were about the same in 3Q 2025 as in 3Q 2024, but were $235 lower in 9M 2025 compared to 9M 2024 from the completion of independent testing and validation of UTMD&#8217;s own-branded biopharmaceutical high-pressure monitoring devices, which it has begun to market. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">12</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">In conjunction with tables in the overview, a division of G&amp;A expenses by location follows. G&amp;A expenses include non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the acquisition of Femcare, as well as litigation expenses:</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:472.5pt"><tr style="height:7.2pt"><td valign="middle" style="width:121.5pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A Exp<br/><span style="border-bottom:1px solid #000000">Category</span></p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;3Q<br/><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="middle" style="width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">3Q<br/><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="middle" style="width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">9M<br/><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td><td valign="middle" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">9M<br/><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">% of<br/><span style="border-bottom:1px solid #000000">sales</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:121.5pt"><p style="font:10pt Times New Roman;margin:0">IIA Amort- UK:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">536</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.5</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">517</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.2</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,568</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.3</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,522</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4.8</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:121.5pt"><p style="font:10pt Times New Roman;margin:0">Other&#8211; UK:</p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">176</p>
</td><td valign="middle" style="width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">187</p>
</td><td valign="middle" style="width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">555</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">536</p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:121.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">U.S. Litigation</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">389</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">4.0</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">413</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">4.1</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">977</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3.3</span></p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,802</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.7</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:121.5pt"><p style="font:10pt Times New Roman;margin:0">Other&#8211; US:</p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">667</p>
</td><td valign="middle" style="width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">582</p>
</td><td valign="middle" style="width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,864</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,740</p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:121.5pt"><p style="font:10pt Times New Roman;margin:0">IRE:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">96</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">87</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">268</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">273</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:121.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">IRE China B/D:</span></p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td valign="middle" style="width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">4.0</span></p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="middle" style="width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">0.0</span></p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1.3</span></p>
</td><td valign="middle" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">0.0</span></p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:121.5pt"><p style="font:10pt Times New Roman;margin:0">AUS:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">32</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">54</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">98</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="width:121.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">CAN:</span></p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">31</span></p>
</td><td valign="middle" style="width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">32</span></p>
</td><td valign="middle" style="width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">100</span></p>
</td><td valign="middle" style="width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">98</span></p>
</td><td valign="middle" style="width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="middle" style="background-color:#D3F0FE;width:121.5pt"><p style="font:10pt Times New Roman;margin:0">Total G&amp;A:</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,310</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">23.5%</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,850</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt;border-right:1.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">18.5%</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:45pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,780</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt;border-right:1pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.6%</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:49.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,069</p>
</td><td valign="middle" style="background-color:#D3F0FE;width:40.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">19.1%</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s Operating Income margin is Operating Income divided by consolidated sales. &#160;Although the UK IIA amortization expense in GBP was the same as in the prior year&#8217;s same periods, the 3Q 2025 Operating Income margin was diluted by 0.3 percentage points, and the 9M 2025 Operating Income margin was diluted by 0.5 percentage points, due to lower sales and stronger GBP FX rate. The significant Femcare IIA amortization expense, representing more than 5% of current revenues, will end in 1Q 2026 after 15 years. Litigation expenses for Filshie product liability claims in the U.S. were lower in both 3Q and 9M 2025 compared to the same periods in 2024, but still significant at more than 3% of WW revenues. As yet, no case has gone to trial, and a majority of cases have been dismissed. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The $460 increase in 3Q 2025 total WW G&amp;A expenses compared to 3Q 2024 was mostly (86%) due to the $395 bad debt provision reserved for cancellation fees charged by UTMD Ireland to its China distributor, resulting in a five-percentage point dilution in UTMD&#8217;s 3Q 2025 Operating Income margin. &#160;Despite that unusual 3Q 2025 expense, 9M 2025 G&amp;A expenses were actually $289 lower than in 9M 2024 due to $825 lower litigation expenses in the U.S., but still diluting the 2025 year-to-date Operating Income margin by 0.5 percentage points due to lower sales.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">U.S. G&amp;A expenses other than litigation were $85 higher in 3Q 2025 compared to 3Q 2024, and $124 higher in 9M 2025 compared to 9M 2024. &#160;About half of the respective year-over-year increases were due to higher U.S. health plan costs, and the other half to non-cash stock option expense increases. &#160;Although G&amp;A headcount remained the same, lower salaries and accrued profit-sharing bonuses offset other increases in outside accounting and other services, director fees and public company administration expenses. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">OUS G&amp;A expenses in USD terms were $1,254 ($1,229 in constant currency) in 3Q 2025 compared to $857 in 3Q 2024. In addition to the $395 bad debt reserve expense in 3Q 2025 which did not occur in 3Q 2024, the total $397 difference was due to $25 impact of FX rate changes from a stronger GBP and EUR. UK IIA amortization expense accounted for $19 of the total $25 increase due to FX rate changes. OUS G&amp;A expenses were $2,940 ($2,876 in constant currency) in 9M 2025 compared to $2,540 in 9M 2024. In addition to the $395 bad debt reserve expense in 9M 2025 which did not occur in 9M 2024, the total $400 difference was due to $64 impact of FX rate changes from a stronger GBP and EUR. UK IIA amortization expense accounted for $46 of the total $64 increase due to FX rate changes.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">In summary, WW Consolidated Revenues (the denominator) and Operating Profit (the numerator) were lower in 2025 time periods compared to 2024 time periods, yielding an Operating Income margin in 3Q 2025 that was 6.8 percentage points lower than in 3Q 2024, and in 9M 2025 that was 3.2 percentage points lower than in 9M 2024. &#160;This yielded an Operating Income margin in 3Q 2025 of 26.6% of sales compared to 33.4% of sales in 3Q 2024; and 30.4% of sales in 9M 2025 compared to 33.6% of sales in 9M 2024. &#160;The primary differences in period-to-period margins can be segmented in terms of percentage-point changes to UTMD&#8217;s Operating Income margin as follows:</p>
<table style="border-collapse:collapse;width:360pt;margin-left:5.4pt"><tr><td valign="top" style="width:175.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Expense Category</span></p>
</td><td valign="top" style="width:94.5pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-5.25pt">3Q Pct-Point<br/><span style="border-bottom:1px solid #000000">Margin Change</span></p>
</td><td valign="top" style="width:90pt"><p style="font:10pt Times New Roman;margin:0">9M Pct-Point<br/><span style="border-bottom:1px solid #000000">Margin Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:175.5pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:94.5pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(0.9)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(2.5)</p>
</td></tr>
<tr><td valign="top" style="width:175.5pt"><p style="font:10pt Times New Roman;margin:0">U.S. Litigation Expense (G&amp;A)</p>
</td><td valign="top" style="width:94.5pt"><p style="font:10pt Times New Roman;margin:0"> &#160;+0.4</p>
</td><td valign="top" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"> &#160;+2.4</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:175.5pt"><p style="font:10pt Times New Roman;margin:0">IIA Amort Exp &#8211;&#160;Femcare (G&amp;A)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:94.5pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(0.3)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(0.5)</p>
</td></tr>
<tr><td valign="top" style="width:175.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">All Other Operating Expenses</span></p>
</td><td valign="top" style="width:94.5pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"> &#160;&#160;(6.0)</span></p>
</td><td valign="top" style="width:90pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"> &#160;&#160;(2.6) &#160;</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:175.5pt"><p style="font:10pt Times New Roman;margin:0">Pct-Point Change in </p>
</td><td valign="top" style="background-color:#D3F0FE;width:94.5pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:175.5pt"><p style="font:10pt Times New Roman;margin:0;margin-left:30pt">Operating Income margin:</p>
</td><td valign="top" style="background-color:#D3F0FE;width:94.5pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(6.8)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:90pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;(3.2)</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">13</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt">Note: &#8220;All Other Operating Expenses&#8221; in the table above includes all consolidated S&amp;M expenses, all R&amp;D expenses and all other consolidated G&amp;A expenses excluding IIA amortization and U.S. Filshie litigation expense. &#160;The $395 China distributor bad debt reserve in 3Q 2025 accounted for 4 percentage points out of the 6-percentage point change in All Other Operating Expenses.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:-6.5pt">To remind stockholders of the Femcare IIA amortization history, the initial IIA portion of the 2011 Femcare UK purchase price was &#163;23,998. After 14.5 years of amortization, the Femcare UK IIA remaining balance is &#163;737 as of the end of 3Q 2025. The Femcare IIA amortization will be complete in March 2026. For both 3Q 2025 and 3Q 2024 in GBP terms, the IIA amortization expense was &#163;397. For both 9M 2025 and 9M 2024, the IIA amortization expense was &#163;1,192. The converted USD amortization expense in each period then varied according to the USD/GBP FX rate, which explains the percentage point difference in IIA amortization expense in IIA Amort Exp - Femcare row in the table above.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">e)</kbd><kbd style="margin-left:22.5pt"></kbd>Non-operating expense/ non-operating income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Non-operating expense includes 1) bank fees; 2) losses from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) losses from disposition of assets. &#160;Non-operating income includes 1) investment income from cash balances; 2) rent of underutilized property; 3) royalties received from licensing the Company&#8217;s technology; 4) gains from dispositions of assets; and 5) gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net non-operating income in 3Q 2025 was $698 compared to $836 non-operating income in 3Q 2024. Net non-operating income in 9M 2025 was $2,043 compared to $2,524 non-operating income in 9M 2024. UTMD realized a $20 remeasured currency balance loss in 9M 2025 compared to a $3 remeasured currency balance gain in 9M 2024. In 9M 2025, after $10,367 use of cash for dividends and share repurchases, UTMD received $485 less in WW interest income from lower average cash balances and lower interest rates than in 9M 2024. &#160;In 9M 2025, UTMD used $7,361 cash for share repurchases compared to $13,259 in 9M 2024. &#160;The 1% excise tax imposed on share repurchases, which reduces non-operating income, was $7 in 3Q 2025 compared to $39 in 3Q 2024, and $74 in 9M 2025 compared to $133 in 9M 2024. &#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">f)</kbd><kbd style="margin-left:22.5pt"></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">EBT results from subtracting net non-operating expense or adding net non-operating income from or to, as applicable, Operating Income. &#160;Consolidated 3Q 2025 EBT was $3,309 (33.7% of sales) compared to $4,179 (41.8% of sales) in 3Q 2024.  Consolidated 9M 2025 EBT was $11,004 (37.3% of sales) compared to $13,188 (41.5% of sales) in 9M 2024. &#160;&#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The EBT of Utah Medical Products, Inc. in the U.S. was $9,518 in 9M 2025 compared to $10,597 in 9M 2024. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 3,466 in 9M 2025 compared to EUR 5,258 in 9M 2024. The US GAAP EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (1,416) in 9M 2025 compared to GBP (2,562) in 9M 2024. The EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 146 in 9M 2025 compared to CAD 222 in 9M 2024. The EBT of UTMD&#8217;s manufacturing subsidiaries varies as a result of intercompany shipments which are eliminated in the consolidation of financial results. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) of $4,170 was 15.9% lower compared to $4,958 in 3Q 2024. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Adjusted consolidated EBITDA of $13,493 in 9M 2025 was 12.7% lower compared to $15,447 in 9M 2024. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $17,898 as of September 30, 2025. At this point, adjusted consolidated EBITDA for 2025 calendar year as a whole is expected to be in the range of $17 to $18 million.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 42.5% in 3Q 2025 compared to 49.6% in 3Q 2024. &#160;UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 45.8% in 9M 2025 compared to 48.7% in 9M 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance during a difficult transition period of time. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:483.5pt;margin-left:5.4pt"><tr><td valign="top" style="width:231.65pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2025</span></p>
</td><td valign="top" style="width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3Q 2024</span></p>
</td><td valign="top" style="width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2025</span></p>
</td><td valign="top" style="width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">9M 2024</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:231.65pt"><p style="font:10pt Times New Roman;margin:0">EBT</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$3,309</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$4,179</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$11,004</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$13,188</p>
</td></tr>
<tr><td valign="top" style="width:231.65pt"><p style="font:10pt Times New Roman;margin:0">Depreciation Expense</p>
</td><td valign="top" style="width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">209</p>
</td><td valign="top" style="width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">203</p>
</td><td valign="top" style="width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">614</p>
</td><td valign="top" style="width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">530</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:231.65pt"><p style="font:10pt Times New Roman;margin:0">Femcare IIA Amortization Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">536</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">517</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,568</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,522</p>
</td></tr>
<tr><td valign="top" style="width:231.65pt"><p style="font:10pt Times New Roman;margin:0">Other Non-Cash Amortization Expense</p>
</td><td valign="top" style="width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 8</p>
</td><td valign="top" style="width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td valign="top" style="width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">25</p>
</td><td valign="top" style="width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">26</p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:231.65pt"><p style="font:10pt Times New Roman;margin:0">Stock Option Compensation Expense</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">95</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">53</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">262</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">184</p>
</td></tr>
<tr><td valign="top" style="width:231.65pt"><p style="font:10pt Times New Roman;margin:0">Interest Expense</p>
</td><td valign="top" style="width:55.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">- </p>
</td><td valign="top" style="width:65.5pt;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:1.5pt;text-align:right">- </p>
</td><td valign="top" style="width:65.5pt;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;margin-right:3.75pt;text-align:right">- </p>
</td><td valign="top" style="width:65.5pt"><p style="font:10pt Times New Roman;margin:0;margin-right:6.75pt;text-align:right">- </p>
</td></tr>
<tr><td valign="top" style="background-color:#D3F0FE;width:231.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Remeasured Foreign Currency Balances</p>
</td><td valign="top" style="background-color:#D3F0FE;width:55.35pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"> 13</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(2)</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">20</p>
</td><td valign="top" style="background-color:#D3F0FE;width:65.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(3)</p>
</td></tr>
<tr><td valign="top" style="width:231.65pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">UTMD non-US GAAP EBITDA:</p>
</td><td valign="top" style="width:55.35pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$4,170</p>
</td><td valign="top" style="width:65.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$4,958</p>
</td><td valign="top" style="width:65.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$13,493</p>
</td><td valign="top" style="width:65.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$15,447</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">g)</kbd><kbd style="margin-left:22.5pt"></kbd>Net Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income is EBT minus a provision for estimated income taxes. &#160;Net Income in 3Q 2025 of $2,631 (26.8% of sales) was 26.2% lower than Net Income of $3,563 (35.6% of sales) in 3Q 2024. Net Income in 9M 2025 of $8,720 (29.6% of sales) was 20.5% lower than Net Income of $10,972 (34.6% of sales) in 9M 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The average consolidated income tax provisions (as a % of the same period EBT) in 3Q 2025 and 3Q 2024 were 20.5% and 14.7% respectively, and were 20.8% and 16.8% in 9M 2025 and 9M 2024 respectively. The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Also, periodic true-up adjustments to the provision occur as actual returns are filed by independent accountants. The EBT in UTMD&#8217;s lowest taxed sovereignty, Ireland, was the hardest hit in 3Q and 9M 2025 from the cancellation of OUS distributor orders and lower OUS sales of the Filshie Clip System, both of which are manufactured and sold by UTMD Ireland. The 9M 2025 EBT in the U.S., taxed at a basic corporate rate of 25.5%, was 86% of total 9M 2025 EBT compared to 80% in 9M 2024. &#160;In addition, the portion of UTMD&#8217;s non-operating income generated from interest on high grade tax-exempt municipal bonds was lower in 2025. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same in 2025 as in 2024. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">h)</kbd><kbd style="margin-left:22.5pt"></kbd>Earnings Per Share (EPS)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Diluted EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). </p>
<p style="font:10pt Times New Roman;margin:0"> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Diluted EPS in 3Q 2025 were $0.820 compared to $1.025 in 3Q 2024, a 19.9% decrease. Diluted shares were 3,207,490 in 3Q 2025 compared to 3,477,797 in 3Q 2024. Diluted EPS in 9M 2025 were $2.680 compared to diluted EPS of $3.098 in 9M 2024, a 13.5% decrease. Diluted shares were 3,254,196 in 9M 2025 compared to 3,541,998 in 9M 2024. The lower number of diluted shares was the result of share repurchases. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The number of shares used for calculating 3Q 2025 EPS was higher than September 30, 2025 actual outstanding shares because of a time-weighted calculation of average outstanding shares. There was no dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2025 were 3,204,172 compared to 3,335,156 at the end of calendar year 2024. The difference was due to 130,984 shares repurchased by UTMD in the open market during 9M 2025. &#160;There were no option exercises in 9M 2025. For further comparison, actual outstanding shares one year ago at the end of 3Q 2024 were 3,440,525, and at the end of 2023 were 3,629,525. The total number of outstanding unexercised employee and outside director options at September 30, 2025 was 97,511 at an average exercise price of $73.75, including shares awarded but not yet vested. &#160;This compares to 73,497 unexercised option shares at the end of 3Q 2024 at an average exercise price of $77.01/ share, including shares awarded but not vested. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Because the average exercise price of employee options was higher than the ending market price of the stock, the number of dilution shares added as a dilution factor for both 3Q 2025 and 9M 2025 was zero. The same was true in 3Q and 9M 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">No employee or director options have been awarded in 9M 2025. Non-qualified option awards of 14,600 shares were made to 47 employees, and an additional 10,000 shares to one new director, in November 2024 at an exercise price of $64.09. UTMD paid $988 ($0.305/share) in dividends to stockholders in 3Q 2025 compared to $1,052 ($0.300/ share) paid in 3Q 2024. Dividends paid to stockholders during 3Q 2025 were 38% of 3Q 2025 Net Income. UTMD paid $3,006 ($0.305/share) in dividends to stockholders in 9M 2025 compared to $3,222 ($0.300/ share) paid in 9M 2024. Dividends paid to stockholders during 9M 2025 were 34% of 9M 2025 Net Income. In 3Q 2025, </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD purchased 11,729 of its shares for $653, at an average cost of $55.67/ share. Total shares purchased in 9M 2025 were 130,984 for $7,362, at an average cost of $56.20/ share. The shares purchased in 9M 2025 represented 3.9% of shares outstanding at the end of 2024. &#160;In comparison, in 3Q 2024, UTMD purchased 58,377 of its shares for $3,866, at an average cost of $66.22/ share. Total shares purchased in 9M 2024 were 196,592 for $13,259, at an average cost of $67.45/ share. The shares purchased in 9M 2024 represented 5.4% of shares outstanding at the end of 2023. Since the end of 2023, when UTMD began to purchase its shares more actively, UTMD has repurchased 432,945 of its shares for $27,329, an average per share cost of $63.12 (representing about 12% of outstanding shares at the end of 2023). In addition, during the same 21- month period of time, UTMD distributed $7,266 in cash dividends to stockholders. In sum, since the end of 2023, UTMD used $34,595 in cash for dividends and share purchases. UTMD&#8217;s cash balance from the end of 2023 to September 30, 2025 has declined just $8,601. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">i) </kbd><kbd style="margin-left:22.5pt"></kbd>Return on Stockholder Equity (ROE) and Stock Value&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;Before the payment of dividends, annualized ROE in 9M 2025 was 10% compared to 12% in 9M 2024. The lower ROE in 9M 2025 was due to lower Net Income. Targeting a high ROE of 20% (before dividends) remains a key financial objective for UTMD management. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD paid $988 ($0.305/share) in dividends to stockholders in 3Q 2025 compared to $1,052 ($0.300/ share) paid in 3Q 2024. Dividends paid to stockholders during 3Q 2025 were 38% of Net Income. UTMD paid $3,006 ($0.305/share) in dividends to stockholders in 9M 2025 compared to $3,222 ($0.300/ share) paid in 9M 2024. Dividends paid to stockholders during 9M 2025 were 34% of Net Income. Share repurchases offset the higher dividend paid per share.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD&#8217;s closing share price at the end of 3Q 2025 was $62.97, up 10.6% from the closing price of $56.92 three months earlier at the end of 2Q 2025, and 2.4% higher than the closing price of $61.47 nine months earlier at the end of 2024. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Liquidity and Capital Resources</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">j)</kbd><kbd style="margin-left:22.5pt"></kbd>Cash flows&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $11,215 in 9M 2025 compared to $11,894 in 9M 2024. &#160;The $679 lower cash provided by operating activities was primarily due to $2,252 lower Net Income, together with a $502 greater decrease in 9M inventories, a $658 lower decrease in accrued expenses and a $395 increase in 9M 2025 bad debt reserve instead of a $5 decrease in 9M 2024. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Capital expenditures for property and equipment (PP&amp;E) were $262 in 9M 2025 compared to $221 in 9M 2024. &#160;The PP&amp;E capital expenditures in 2025 were normal equipment replacement, not for expansion. PP&amp;E capital expenditures in both years&#8217; 9M periods were much less than non-cash depreciation expense. &#160;Depreciation of PP&amp;E in 9M 2025 was $614 compared to $530 in 9M 2024. There were no capital expenditures for intangible assets in 9M 2025 compared to $5 in 9M 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD made cash dividend payments of $3,006 in 9M 2025 compared to $3,222 in 9M 2024. &#160;UTMD used $7,361 cash for share repurchases in 9M 2025 compared to $13,259 for share repurchases in 9M 2024. &#160;In the form of dividends and share repurchases, UTMD returned $10,367 to stockholders in 9M 2025 compared to $16,481 in 9M 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In 9M 2025, there were no employee stock option exercises. &#160;In 9M 2024 (actually all in 1H 2024), the Company received $390 and issued 7,592 shares of stock on the exercise of employee stock options. Option exercises in 9M 2024 were at an average price of $51.39 per share. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company intends to utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">k)</kbd><kbd style="margin-left:22.5pt"></kbd>Assets and Liabilities&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">September 30, 2025 total consolidated assets were $121,975, a net decrease of $564 from December 31, 2024. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated Current Assets alone increased $201, as cash increased $1,291 while inventories decreased $694 and receivables decreased $370. The $564 total asset decrease, in spite of the $201 current asset increase and a $237 increase in WW net PP&amp;E, was due to a $1,002 decrease in Net Intangible Assets (IIA).  </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Net IIA declined as a result of amortization combined with a stronger GBP for remaining Femcare IIA. September 30, 2025 Net Intangible Assets (goodwill plus other intangible assets, less amortization) declined $1,002 from the end of 2024. &#160;No intangible assets were acquired in 9M 2025. &#160;At September 30, 2025, Net Intangible Assets including goodwill were 12.7% of consolidated Total Assets compared to 13.4% at year-end 2024, and 13.6% one year ago at September 30, 2024. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The net book value of WW consolidated USD PP&amp;E increased $237 at September 30, 2025 from the end of 2024 due to the combination of period-ending changed FX rates, $262 in new asset purchases and $614 in depreciation. Despite depreciation exceeding new purchases by $352, the $237 increase in total consolidated PP&amp;E net book value resulted from the impact of stronger foreign currencies in Ireland and the UK when converting the net book value of PP&amp;E in Ireland and the UK to USD. &#160;UTMD&#8217;s Ireland subsidiary EUR-denominated assets and liabilities on September 30, 2025 were translated into USD at a foreign currency exchange (FX) rate 13.4% higher (stronger EUR relative to the USD) than the FX rate at the end of 2024. UTMD&#8217;s UK subsidiary GBP-denominated assets were translated into USD at an FX rate 7.4% higher (stronger GBP) than the FX rate at the end of 2024. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Working capital (Current Assets minus Current Liabilities) was $93,521 at September 30, 2025 compared to $92,574 at December 31, 2024. &#160;The primary source of the $947 working capital increase was from a consolidated increase of $1,291 in cash. &#160;Noncash working capital, independent from the change in cash, decreased $344 as Receivables decreased $370 and inventories decreased $694, while the $698 remaining repatriation tax balance on 12-31-24 was paid off. &#160;Receivables at the end of 3Q 2025 decreased because sales were lower. Days in trade receivables at the end of 3Q 2025 at 34 were about the same as at the end of 3Q 2024. Management believes that UTMD&#8217;s working capital remains sufficient to meet normal operating needs, as well as providing a cushion for unpredictable short-term negative events, new capital expenditures and continued cash dividend payments to stockholders.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The long-term deferred tax liability (DTL) balance for Femcare IIA ($9,084 on the date of the acquisition) was $248 (&#163;184) at September 30, 2025, compared to $604 (&#163;482) at December 31, 2024, and $779 (&#163;582) at September 30, 2024. &#160;Reduction of the DTL occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare IIA (because the amortization expense is not tax deductible in the UK). The DTL declined $356 at September 30, 2025 from December 31, 2024, as a result of 9M 2025 amortization expense of $1,568, which reduced the DTL balance by $392 (using UK tax rate = 25%). The remaining difference was due to the FX rate change when converting the GBP to USD at September 30, 2025. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s total debt ratio (Total Liabilities/ Total Assets) as of September 30, 2025 was 3%, with no remaining IRC 956 Repatriation Tax liability from the 2017 &#8220;Tax Cuts and Jobs Act&#8221;. &#160;UTMD&#8217;s total debt ratio as of December 31, 2024 was 4%, and as of September 30, 2024 was 4%. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The $564 decrease in Total Liabilities and Stockholders&#8217; Equity (same as the decrease in Total Assets) at September 30, 2025 from December 31, 2024 was due to offsetting a $1,388 decline in Total Liabilities with an $824 increase in Stockholders&#8217; Equity. The 9M 2025 $10,367 in stockholder dividends and share repurchases reduced Stockholders&#8217; Equity, while the $8,720 in 9M 2025 Net Income increased Stockholders&#8217; Equity. The remaining difference was due to FX rate changes in OUS balance sheet values.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">l)</kbd><kbd style="margin-left:22.5pt"></kbd>Management's Outlook&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-indent:-9pt;margin-left:9pt">As outlined in its December 31, 2024 SEC 10-K report, UTMD&#8217;s plan for 2025 was to</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:27pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-19.5pt">1)</kbd>exploit its pre-qualified status to introduce a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">2)</kbd>continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations; &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:25.5pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3)</kbd>focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.;&#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:9pt"><kbd style="margin-left:-1.8pt"></kbd>4) &#160;&#160;&#160;introduce additional products helpful to clinicians through product development; &#160;</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;margin-left:9pt"><kbd style="margin-left:-1.8pt"></kbd>5) &#160;&#160;&#160;continue to achieve excellent overall financial operating performance despite a contraction in revenues; &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;text-indent:-27pt;margin-left:27pt"> &#160;&#160;6) &#160;&#160;&#160;utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued; and</p>
<p style="font:10pt Times New Roman;margin-top:2pt;margin-bottom:0pt;text-indent:-27pt;margin-left:27pt"> &#160;&#160;7) &#160;&#160;&#160;remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">Although UTMD&#8217;s 2025 plan remains unchanged, annual sales are expected to be lower than anticipated due to changed demand from OUS distributors. &#160;Management believes this was caused by reciprocal tariffs. &#160;With the lower OUS revenues offset by higher sales of the Filshie Clip System in the U.S. and neonatal devices WW, together with likely increasing sales to biopharm customers in 4Q 2025, revenues for the full 2025 year are now expected to be 6-7% lower than in 2024, and EPS in the range of $3.40-3.50. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"> &#160;</kbd><kbd style="position:absolute;font:10pt Times New Roman;margin-left:9pt">m)</kbd><kbd style="margin-left:22.5pt"></kbd>Accounting Policy Changes&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">None</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>Forward-Looking Information</b>. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a8"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .8523, .9661 and .8974 EUR per USD as of September 30, 2025, December 31, 2024 and September 30, 2024, respectively. &#160;Exchange rates were .7439, .7987 and .7465 GBP per USD as of September 30, 2025, December 31, 2024 and September 30, 2024, respectively. &#160;Exchange rates were 1.5122, 1.6172 and 1.4428 AUD per USD on September 30, 2025, December 31, 2024, and September 30, 2024, respectively. &#160;Exchange rates were 1.3516, 1.3930, and 1.4403 CAD per USD on September 30, 2025, December 31, 2024, and September 30, 2024, respectively. UTMD manages its foreign currency risk without separate hedging transactions by invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and by optimizing global account structures through liquidity management accounts.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a9"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 4. Controls and Procedures</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2025. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2025, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:24.5pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the nine months ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">18</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">PART II - OTHER INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a10"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 1. &#160;&#160;&#160;&#160;Legal Proceedings</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD is a party from time to time in litigation incidental to its business. Presently, except for Filshie clip U.S. product liability lawsuits, with most having received dismissals, there is no litigation or threatened litigation. The Company does not expect the outcome of the remaining Filshie clip litigation will be material to consolidated financial results.  </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a11"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 1A.</b></kbd><kbd style="margin-left:46.8pt"></kbd><b>Risk Factors &#160;</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#333333">In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a12"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 2.</b></kbd><kbd style="margin-left:37.8pt"></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The following table details purchases by UTMD of its own securities during 3Q 2025.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-align:center"><b>ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse;width:481.05pt;border:0.5pt solid #000000"><tr style="height:107.7pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Period</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(a)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased (1)</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(b)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Average price paid per share (1)</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(c)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased as part of publicly announced plans or programs (1)</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(d)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">07/01/25 &#8211;&#160;07/31/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,941</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">55.76</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">08/01/25 &#8211;&#160;08/31/25</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,788</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">55.40</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:13.55pt"><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">09/01/25 &#8211;&#160;09/30/25</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">-</span></p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#D3F0FE;width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:12.8pt"><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,729</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">55.67</p>
</td><td valign="top" style="width:96.2pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:8pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:-18pt">1)</kbd>None of the shares were purchased as part of a specific publicly-announced plan and all were purchased on the open market.&#160;</p>
<p style="font:8pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:8pt Times New Roman;margin-left:-18pt">2)</kbd>The total number of shares repurchased to-date in 2025 through November 10 was 131,484 at an average cost of $56.21/ share, approximately 4% of prior year-end 2024 outstanding shares.&#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The frequency of UTMD&#8217;s open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD&#8217;s continuing and long-term pattern of opportunistic open market share repurchases since 1992. &#160;</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The purpose of UTMD&#8217;s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business<span style="color:#FF0000">. </span>UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">19</p>
<hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a13"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 6. &#160;Exhibits </b></p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr style="height:14.4pt"><td valign="bottom" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Exhibit #</span></p>
</td><td valign="bottom" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">SEC <span style="border-bottom:1px solid #000000">Reference #</span></p>
</td><td valign="bottom" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Title of Document</span></p>
</td></tr>
<tr style="height:3.6pt"><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z1.htm" style="text-decoration:none">Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101 ins</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Instance</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">6</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.sch</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Schema</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.cal</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Calculation</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">8</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.def</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Definition</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">9</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.lab</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Label</p>
</td></tr>
<tr><td valign="top" style="width:50.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">10</p>
</td><td valign="top" style="width:63pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101.pre</p>
</td><td valign="top" style="width:358.2pt"><p style="font:10pt Times New Roman;margin:0">XBRL Presentation</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<a id="a14"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">SIGNATURES</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:28.8pt"></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd>REGISTRANT&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/14/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Kevin L. Cornwell&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>CEO&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/14/25 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Brian L. Koopman&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:219.1pt"></kbd>Principal Financial Officer&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:right"><b> </b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> &#160;</p>
<p style="font:10pt Times New Roman;margin:0"> &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0;text-align:center">20</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 14, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 14, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 14, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I><BR></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:403.2pt></KBD><B>Exhibit 32.2</B>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 14, 2025</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. &nbsp;</I></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3Inventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(9) Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:to='lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2025, 3,204 shares and December 31, 2024, 3,335 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross Profit Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossProfitMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Gross Profit Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossProfitMargin' xlink:to='lab_fil_GrossProfitMargin'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(4) Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of right of use assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(7) Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {4}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherInterestAndDividendIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Interest and Dividend Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherInterestAndDividendIncome' xlink:to='lab_us-gaap_OtherInterestAndDividendIncome'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Selling, General and Administrative Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Income Margin</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingIncomeMargin' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the percentage value of Operating Income Margin, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OperatingIncomeMargin' xlink:to='lab_fil_OperatingIncomeMargin'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Litigation Expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LitigationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Litigation Expense, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LitigationExpense' xlink:to='lab_fil_LitigationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SegmentReportingDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(8) Segment Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SegmentReportingDisclosureTextBlock' xlink:to='lab_us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Finished Goods, Net of Reserves</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(6) Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(1) Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherOperatingIncomeExpenseNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Operating Income (Expense), Net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherOperatingIncomeExpenseNet' xlink:to='lab_us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingAndMarketingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling and Marketing Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingAndMarketingExpense' xlink:to='lab_us-gaap_SellingAndMarketingExpense'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Other cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OtherCostOfSales' xlink:to='lab_fil_OtherCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(3) Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(2) Recent Accounting Standards</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaidNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaidNet' xlink:to='lab_us-gaap_InterestPaidNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Single Operating Segment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SingleOperatingSegmentMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Single Operating Segment, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SingleOperatingSegmentMember' xlink:to='lab_fil_SingleOperatingSegmentMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ScenarioUnspecifiedDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ScenarioUnspecifiedDomain' xlink:to='lab_srt_ScenarioUnspecifiedDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Segment Reporting Information, by Segment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:to='lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase/(decrease) in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase/(decrease) in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard cost of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StandardCostOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Standard cost of sales, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StandardCostOfSales' xlink:to='lab_fil_StandardCostOfSales'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(5) Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLongTermDebtNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLongTermDebtNoncurrent' xlink:to='lab_us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Work in Process, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Global Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Schedule of Global Revenues by Product Category.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:to='lab_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementScenarioAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Scenario [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementScenarioAxis' xlink:to='lab_srt_StatementScenarioAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, Raw Materials, Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details {3}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20250930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Assets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermDebtNoncurrent' xlink:label='us-gaap_OtherLongTermDebtNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_OtherLongTermDebtNoncurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' xlink:label='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet' xlink:label='us-gaap_InterestPaidNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaidNet' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure1BasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure2RecentAccountingStandards"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3Inventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure4StockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure5WarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock' xlink:label='us-gaap_SegmentReportingDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SegmentReportingDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure9SubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' xlink:label='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' xlink:label='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure4StockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" xlink:type="simple" xlink:href="utmd-20250930.xsd#idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis' xlink:label='srt_StatementScenarioAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementScenarioAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain' xlink:label='srt_ScenarioUnspecifiedDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='srt_ScenarioUnspecifiedDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_SingleOperatingSegmentMember' xlink:label='fil_SingleOperatingSegmentMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementScenarioAxis' xlink:to='fil_SingleOperatingSegmentMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_StandardCostOfSales' xlink:label='fil_StandardCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StandardCostOfSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OtherCostOfSales' xlink:label='fil_OtherCostOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherCostOfSales' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_GrossProfitMargin' xlink:label='fil_GrossProfitMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossProfitMargin' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense' xlink:label='us-gaap_SellingAndMarketingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SellingAndMarketingExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_LitigationExpense' xlink:label='fil_LitigationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LitigationExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_OtherSellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherSellingGeneralAndAdministrativeExpense' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20250930.xsd#fil_OperatingIncomeMargin' xlink:label='fil_OperatingIncomeMargin'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OperatingIncomeMargin' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInterestAndDividendIncome' xlink:label='us-gaap_OtherInterestAndDividendIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherInterestAndDividendIncome' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet' xlink:label='us-gaap_OtherOperatingIncomeExpenseNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherOperatingIncomeExpenseNet' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='17.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.utahmed.com/20250930' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://www.utahmed.com/20250930' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2025' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2024-01-31' xmlns:srt='http://fasb.org/srt/2025' xmlns:us-gaap='http://fasb.org/us-gaap/2025'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails">
				<link:definition>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails" id="idr_Disclosure4StockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - (4) Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation" id="idr_Disclosure4StockBasedCompensation">
				<link:definition>000110 - Disclosure - (4) Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare" id="idr_Disclosure7EarningsPerShare">
				<link:definition>000140 - Disclosure - (7) Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails">
				<link:definition>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation" id="idr_Disclosure8SegmentInformation">
				<link:definition>000150 - Disclosure - (8) Segment Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents" id="idr_Disclosure9SubsequentEvents">
				<link:definition>000160 - Disclosure - (9) Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition" id="idr_Disclosure6RevenueRecognition">
				<link:definition>000130 - Disclosure - (6) Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories" id="idr_Disclosure3Inventories">
				<link:definition>000100 - Disclosure - (3) Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables" id="idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables">
				<link:definition>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards" id="idr_Disclosure2RecentAccountingStandards">
				<link:definition>000090 - Disclosure - (2) Recent Accounting Standards</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables">
				<link:definition>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation" id="idr_Disclosure1BasisOfPresentation">
				<link:definition>000080 - Disclosure - (1) Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables" id="idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables">
				<link:definition>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails" id="idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails">
				<link:definition>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails" id="idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve" id="idr_Disclosure5WarrantyReserve">
				<link:definition>000120 - Disclosure - (5) Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2024-01-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2024-01-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2025/dei-2025.xsd' namespace='http://xbrl.sec.gov/dei/2025'/>
	<import schemaLocation='https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd' namespace='http://fasb.org/srt/2025'/>
	<import schemaLocation='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd' namespace='http://fasb.org/us-gaap/2025'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_StandardCostOfSales' name='StandardCostOfSales'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_OtherCostOfSales' name='OtherCostOfSales'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GrossProfitMargin' name='GrossProfitMargin'/>
	<element nillable='true' type='dtr-types:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OperatingIncomeMargin' name='OperatingIncomeMargin'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SingleOperatingSegmentMember' name='SingleOperatingSegmentMember'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_LitigationExpense' name='LitigationExpense'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock' name='ScheduleofglobalrevenuesbyproductcategoryTextBlock'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,203,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 84,267<span></span>
</td>
<td class="nump">$ 82,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,725<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,118<span></span>
</td>
<td class="nump">8,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">96,532<span></span>
</td>
<td class="nump">96,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">9,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,051<span></span>
</td>
<td class="nump">13,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">55,948<span></span>
</td>
<td class="nump">53,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(54,556)<span></span>
</td>
<td class="num">(50,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">121,975<span></span>
</td>
<td class="nump">122,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2025, 3,204 shares and December 31, 2024, 3,335 shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(9,738)<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">127,958<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">118,252<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 121,975<span></span>
</td>
<td class="nump">$ 122,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Details {1}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Details {2}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 10,005<span></span>
</td>
<td class="nump">$ 29,475<span></span>
</td>
<td class="nump">$ 31,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,208<span></span>
</td>
<td class="nump">4,203<span></span>
</td>
<td class="nump">12,738<span></span>
</td>
<td class="nump">12,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">5,802<span></span>
</td>
<td class="nump">16,737<span></span>
</td>
<td class="nump">18,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,826<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
<td class="nump">7,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">7,776<span></span>
</td>
<td class="nump">8,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">8,961<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,631<span></span>
</td>
<td class="nump">$ 3,563<span></span>
</td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="num">$ (376)<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 4,995<span></span>
</td>
<td class="nump">$ 10,890<span></span>
</td>
<td class="nump">$ 11,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Details {2}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
<td class="num">$ (10,658)<span></span>
</td>
<td class="nump">$ 138,341<span></span>
</td>
<td class="nump">$ 128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,090)<span></span>
</td>
<td class="num">(13,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,171)<span></span>
</td>
<td class="num">(3,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,972<span></span>
</td>
<td class="nump">10,972<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,890)<span></span>
</td>
<td class="nump">134,053<span></span>
</td>
<td class="nump">124,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,322)<span></span>
</td>
<td class="nump">135,339<span></span>
</td>
<td class="nump">124,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions', window );">Common stock received and retired upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,812)<span></span>
</td>
<td class="num">(3,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,038)<span></span>
</td>
<td class="num">(1,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,890)<span></span>
</td>
<td class="nump">134,053<span></span>
</td>
<td class="nump">124,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,908)<span></span>
</td>
<td class="nump">129,302<span></span>
</td>
<td class="nump">117,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,098)<span></span>
</td>
<td class="num">(7,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,966)<span></span>
</td>
<td class="num">(2,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,720<span></span>
</td>
<td class="nump">8,720<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2025</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,738)<span></span>
</td>
<td class="nump">127,958<span></span>
</td>
<td class="nump">118,252<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2025</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2025</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,362)<span></span>
</td>
<td class="nump">126,862<span></span>
</td>
<td class="nump">117,533<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(558)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(977)<span></span>
</td>
<td class="num">(977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2025</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (9,738)<span></span>
</td>
<td class="nump">$ 127,958<span></span>
</td>
<td class="nump">$ 118,252<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2025</a></td>
<td class="nump">3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="nump">395<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(641)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Accounts receivable and other receivables</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(802)<span></span>
</td>
<td class="num">(1,460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">11,215<span></span>
</td>
<td class="nump">11,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(7,361)<span></span>
</td>
<td class="num">(13,259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,006)<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(10,367)<span></span>
</td>
<td class="num">(16,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">705<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="num">(4,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">82,976<span></span>
</td>
<td class="nump">92,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">84,267<span></span>
</td>
<td class="nump">88,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income); loss (gain); increase (decrease) in liability and (increase) decrease in asset used in operating activity; and cash inflow (outflow) from operating activity, classified as other; in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(1) Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">(1) Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(1)</kbd><kbd style="margin-left:19.8pt"></kbd>The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(2) Recent Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">(2) Recent Accounting Standards</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">(3) Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(3)</kbd><kbd style="margin-left:19.8pt"></kbd>Inventories at September 30, 2025, and December 31, 2024, consisted of the following:&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:93.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"></td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:97.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">1,224</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:93.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">1,913</kbd>&#160;</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">1,606</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:93.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">1,414</kbd>&#160;</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">5,288</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">5,485</kbd>&#160;</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">8,118</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:93.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">8,812</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">(4) Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(4)</kbd><kbd style="margin-left:18pt"></kbd>Stock-Based Compensation. At September 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2025, and 2024, the Company recognized $95 and $53, respectively, in stock-based compensation cost. &#160;In the nine months ended September 30, 2025, and 2024, the Company recognized $262 and $184, respectively, in stock-based compensation cost.&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(5) Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">(5) Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">(5) </kbd><kbd style="margin-left:18pt"></kbd>Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024, or September 30, 2025. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">(6) Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) Global 3Q 2025 revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:184.5pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">869</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">170</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">1,039</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,521</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">2,433</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">4,954</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">1,622</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">554</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">2,176</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessorie</span>s*</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">847</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">796</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">1,643</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total:</span></p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">5,859</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">3,953</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">9,812</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2025 revenues (USD) by product category:</p>
<table style="border-collapse:collapse"><tr><td style="width:184.5pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,519</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">570</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">3,089</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">7,272</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">7,384</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">14,656</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">4,981</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">1,280</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">6,261</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessories*</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,536</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">2,933</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">5,469</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total</span></p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0">:</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">17,308</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">12,167</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">29,475</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">*includes assemblies and molded components sold to OEM customers. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(7) Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3<span style="vertical-align:super">rd</span> quarter 2025.</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: <i>(in thousands)</i>:</p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"></td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,631</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,563</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,720</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,972</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,207</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,478</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,254</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,542</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,207</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,478</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,254</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,542</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.82</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.02</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.68</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.10</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.82</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.02</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.68</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.10</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">(8) Segment Information</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table presents selected financial information with respect to the Company&#8217;s single operating segment for the quarters ended September 30, 2025 and September 30, 2024:</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended September 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,812</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,005</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,359</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,456</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">849</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">747</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,604</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,802</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">57.1%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">58.0%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">516</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">437</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">167</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">171</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">384</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">426</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">544</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">525</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,382</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">900</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,611</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,343</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">26.6%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">33.4%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">719</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">872</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(21)</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(36)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,309</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,179</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">678</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">615</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,631</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,564</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(9) Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">(9) Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements. After September 30, 2025 through November 10, 2025, the Company made additional repurchases of 500 shares of its stock in the open market for $29, at a price of $57.90 per share.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:93.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31,</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"></td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">2025</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#D3F0FE;width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:97.35pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">1,224</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:93.6pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">1,913</kbd>&#160;</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">1,606</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:93.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">1,414</kbd>&#160;</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#D3F0FE;width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">5,288</kbd>&#160;</p>
</td><td style="background-color:#D3F0FE;width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">5,485</kbd>&#160;</p>
</td></tr>
<tr><td style="width:141.6pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total </p>
</td><td style="width:60.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:97.35pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt">8,118</kbd>&#160;</p>
</td><td style="width:11.8pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:93.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt">8,812</kbd>&#160;</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock', window );">Schedule Of Global Revenues By Product Category</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse"><tr><td style="width:184.5pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">869</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">170</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">1,039</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,521</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">2,433</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">4,954</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">1,622</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">554</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">2,176</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessorie</span>s*</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">847</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">796</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">1,643</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total:</span></p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">5,859</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right">3,953</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">9,812</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2025 revenues (USD) by product category:</p>
<table style="border-collapse:collapse"><tr><td style="width:184.5pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Domestic</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"><span style="border-bottom:1px solid #000000">Outside US</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"><span style="border-bottom:1px solid #000000">Total</span></p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Labor &amp; Delivery</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,519</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">570</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">3,089</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">7,272</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">7,384</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">14,656</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">4,981</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">1,280</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:43.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">6,261</p>
</td></tr>
<tr><td style="width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Blood Pressure Monitoring and Accessories*</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">2,536</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">2,933</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">5,469</p>
</td></tr>
<tr><td style="background-color:#D3F0FE;width:184.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"><span style="color:#000000">Total</span></p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0">:</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right">17,308</p>
</td><td style="background-color:#D3F0FE;width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right">12,167</p>
</td><td style="background-color:#D3F0FE;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right">29,475</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Global Revenues by Product Category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:131.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:153pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"></td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2025</span></p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">2024</span></p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,631</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,563</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,720</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,972</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,207</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,478</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,254</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,542</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,207</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,478</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,254</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,542</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE;width:53.45pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.82</p>
</td><td style="width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.02</p>
</td><td style="width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.68</p>
</td><td style="width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.10</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#D3F0FE;width:149.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="background-color:#D3F0FE;width:53.45pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.82</p>
</td><td style="background-color:#D3F0FE;width:15.3pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:63pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.02</p>
</td><td style="background-color:#D3F0FE;width:18pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:72pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.68</p>
</td><td style="background-color:#D3F0FE;width:13.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;width:67.5pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3.10</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<table style="border-collapse:collapse"><tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Quarter Ended September 30,</b></p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"></td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2025</b></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>2024</b></p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Revenues</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,812</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,005</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Less:</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Standard cost of sales</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,359</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,456</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other cost of sales</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">849</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">747</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,604</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,802</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gross Profit Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">57.1%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">58.0%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Sales &amp; Marketing</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">516</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">437</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Research &amp; Development</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">167</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">171</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Litigation Fees</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">384</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">426</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Amortization</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">544</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">525</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Other General &amp; Administrative</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,382</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">900</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,611</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,343</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Income Margin</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">26.6%</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">33.4%</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other Income</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Interest income</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">719</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">872</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Other income (expense)</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(21)</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(36)</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Income before income taxes</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,309</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,179</p>
</td></tr>
<tr style="height:7.2pt"><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">678</p>
</td><td style="background-color:#D3F0FE" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">615</p>
</td></tr>
<tr style="height:7.2pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Net Income</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,631</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,564</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>(3) Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">$ 1,224<span></span>
</td>
<td class="nump">$ 1,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">5,288<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 8,118<span></span>
</td>
<td class="nump">$ 8,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(4) Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 10,005<span></span>
</td>
<td class="nump">$ 29,475<span></span>
</td>
<td class="nump">$ 31,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,631<span></span>
</td>
<td class="nump">$ 3,563<span></span>
</td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">$ 10,005<span></span>
</td>
<td class="nump">$ 29,475<span></span>
</td>
<td class="nump">$ 31,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">5,802<span></span>
</td>
<td class="nump">16,737<span></span>
</td>
<td class="nump">18,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">8,961<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,631<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 10,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember', window );">Single Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">9,812<span></span>
</td>
<td class="nump">10,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_StandardCostOfSales', window );">Standard cost of sales</a></td>
<td class="nump">3,359<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_OtherCostOfSales', window );">Other cost of sales</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 5,604<span></span>
</td>
<td class="nump">$ 5,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_GrossProfitMargin', window );">Gross Profit Margin</a></td>
<td class="nump">57.10%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and Marketing Expense</a></td>
<td class="nump">$ 516<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_LitigationExpense', window );">Litigation Expense</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Other Selling, General and Administrative Expense</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">$ 2,611<span></span>
</td>
<td class="nump">$ 3,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_OperatingIncomeMargin', window );">Operating Income Margin</a></td>
<td class="nump">26.60%<span></span>
</td>
<td class="nump">33.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInterestAndDividendIncome', window );">Other Interest and Dividend Income</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Operating Income (Expense), Net</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,631<span></span>
</td>
<td class="nump">$ 3,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossProfitMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Gross Profit Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossProfitMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LitigationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Litigation Expense, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LitigationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OperatingIncomeMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage value of Operating Income Margin, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OperatingIncomeMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OtherCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Other cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OtherCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StandardCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary amount of Standard cost of sales, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StandardCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInterestAndDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInterestAndDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=fil_SingleOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>136</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - (1) Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation</Role>
      <ShortName>(1) Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - (2) Recent Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards</Role>
      <ShortName>(2) Recent Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - (3) Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories</Role>
      <ShortName>(3) Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - (4) Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation</Role>
      <ShortName>(4) Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - (5) Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve</Role>
      <ShortName>(5) Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - (6) Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition</Role>
      <ShortName>(6) Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - (7) Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare</Role>
      <ShortName>(7) Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - (8) Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation</Role>
      <ShortName>(8) Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - (9) Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents</Role>
      <ShortName>(9) Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>(3) Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - (4) Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails</Role>
      <ShortName>(4) Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails</Role>
      <ShortName>(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20250930_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails</Role>
      <ShortName>(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>utmd-20250930.xsd</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20250930_10q.htm">utmd-20250930_10q.htm</File>
    <File>utmd-20250930_cal.xml</File>
    <File>utmd-20250930_def.xml</File>
    <File>utmd-20250930_lab.xml</File>
    <File>utmd-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="458">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>42
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250930_10q.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "utmd-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "utmd-20250930_10q.htm"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 129,
   "keyCustom": 7,
   "axisStandard": 4,
   "axisCustom": 0,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 81,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 182,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 458,
    "http://xbrl.sec.gov/dei/2025": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E23_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E23_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation",
     "longName": "000080 - Disclosure - (1) Basis of Presentation",
     "shortName": "(1) Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards",
     "longName": "000090 - Disclosure - (2) Recent Accounting Standards",
     "shortName": "(2) Recent Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories",
     "longName": "000100 - Disclosure - (3) Inventories",
     "shortName": "(3) Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation",
     "longName": "000110 - Disclosure - (4) Stock-Based Compensation",
     "shortName": "(4) Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve",
     "longName": "000120 - Disclosure - (5) Warranty Reserve",
     "shortName": "(5) Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition",
     "longName": "000130 - Disclosure - (6) Revenue Recognition",
     "shortName": "(6) Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare",
     "longName": "000140 - Disclosure - (7) Earnings Per Share",
     "shortName": "(7) Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation",
     "longName": "000150 - Disclosure - (8) Segment Information",
     "shortName": "(8) Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents",
     "longName": "000160 - Disclosure - (9) Subsequent Events",
     "shortName": "(9) Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables",
     "longName": "000170 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables",
     "longName": "000180 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables",
     "longName": "000190 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables",
     "longName": "000200 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250101_250930",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - (3) Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "(3) Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E25Q3",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails",
     "longName": "000220 - Disclosure - (4) Stock-Based Compensation (Details)",
     "shortName": "(4) Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:StockOptionPlanExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
     "longName": "000230 - Disclosure - (6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "shortName": "(6) Revenue Recognition: Schedule Of Global Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
     "longName": "000240 - Disclosure - (7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "shortName": "(7) Earnings Per Share: Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
     "longName": "000250 - Disclosure - (8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "(8) Segment Information: Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y25Q3",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "kbd",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y25Q3_StScenario-SingleOperatingSeg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250930_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r471"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r561",
      "r562",
      "r563",
      "r564",
      "r586",
      "r622"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "Amount of expense (income); loss (gain); increase (decrease) in liability and (increase) decrease in asset used in operating activity; and cash inflow (outflow) from operating activity, classified as other; in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r100",
      "r181",
      "r183",
      "r433",
      "r437",
      "r438",
      "r440",
      "r442"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r63",
      "r84",
      "r107",
      "r108",
      "r109",
      "r143",
      "r150",
      "r158",
      "r161",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r244",
      "r261",
      "r320",
      "r321",
      "r325",
      "r385",
      "r451",
      "r452",
      "r457",
      "r471",
      "r485",
      "r486",
      "r497",
      "r579",
      "r580",
      "r588"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r244",
      "r261",
      "r471",
      "r579",
      "r580",
      "r588"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; investments",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r81",
      "r434"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r106"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase/(decrease) in cash and cash equivalents",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r48"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r561",
      "r562",
      "r564",
      "r586",
      "r620",
      "r622"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r373"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r373",
      "r391",
      "r622",
      "r623"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2025, 3,204 shares and December 31, 2024, 3,335 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r205",
      "r208",
      "r327",
      "r471"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r89",
      "r91",
      "r95",
      "r318",
      "r334",
      "r335"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r281",
      "r438",
      "r443",
      "r469",
      "r549"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r65",
      "r557",
      "r560"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r326"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16",
      "r99",
      "r437",
      "r438",
      "r440",
      "r442"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(4) Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r461"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r203",
      "r220",
      "r235",
      "r238",
      "r259",
      "r260",
      "r319",
      "r336",
      "r444"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per common share (diluted)",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r203",
      "r220",
      "r235",
      "r238",
      "r259",
      "r260",
      "r319",
      "r336",
      "r444"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(7) Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r139",
      "r140",
      "r141"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r71",
      "r72",
      "r92",
      "r93",
      "r94",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r144",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r276",
      "r333",
      "r345",
      "r346",
      "r347",
      "r359",
      "r409"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r178",
      "r182",
      "r433"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r182",
      "r282",
      "r433"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r179",
      "r317",
      "r452",
      "r456",
      "r463",
      "r464",
      "r465",
      "r466",
      "r470",
      "r471",
      "r573",
      "r574",
      "r585"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r42",
      "r62",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r261",
      "r447",
      "r451",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r579"
     ]
    },
    "fil_GrossProfitMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "GrossProfitMargin",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit Margin",
        "documentation": "Represents the percentage value of Gross Profit Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r58",
      "r62",
      "r320",
      "r322",
      "r331",
      "r439",
      "r441",
      "r443",
      "r447",
      "r451",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {2}",
        "terseLabel": "Details",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r107",
      "r128",
      "r129",
      "r143",
      "r153",
      "r161",
      "r225",
      "r226",
      "r229",
      "r337",
      "r439",
      "r441",
      "r443",
      "r462"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r556",
      "r582",
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r575",
      "r576"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r104",
      "r105"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(3) Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r436"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r435",
      "r471"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r241",
      "r244",
      "r245",
      "r261",
      "r372",
      "r446",
      "r457",
      "r497",
      "r579",
      "r588",
      "r589"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r57",
      "r329",
      "r471",
      "r485",
      "r486",
      "r557",
      "r559",
      "r572",
      "r587"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r80",
      "r107",
      "r108",
      "r109",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r241",
      "r244",
      "r245",
      "r261",
      "r471",
      "r579",
      "r588",
      "r589"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "fil_LitigationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "LitigationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Expense",
        "documentation": "Represents the monetary amount of Litigation Expense, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure2RecentAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(2) Recent Accounting Standards",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70",
      "r72",
      "r114",
      "r115",
      "r118",
      "r119",
      "r130",
      "r131",
      "r169",
      "r173",
      "r174",
      "r200",
      "r201",
      "r220",
      "r221",
      "r233",
      "r234",
      "r236",
      "r238",
      "r251",
      "r257",
      "r275",
      "r277",
      "r278",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expense",
        "totalLabel": "Total operating expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r439",
      "r443",
      "r447",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "fil_OperatingIncomeMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "OperatingIncomeMargin",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Margin",
        "documentation": "Represents the percentage value of Operating Income Margin, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right of use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure1BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(1) Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r73",
      "r74",
      "r76",
      "r353",
      "r354"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r471"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r333"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r262",
      "r269"
     ]
    },
    "fil_OtherCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "OtherCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other cost of sales",
        "documentation": "Represents the monetary amount of Other cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInterestAndDividendIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInterestAndDividendIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Interest and Dividend Income",
        "documentation": "Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r371"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r469"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment {1}",
        "terseLabel": "Property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r281",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r431",
      "r438",
      "r441",
      "r443",
      "r458",
      "r459",
      "r480",
      "r481",
      "r482",
      "r484",
      "r487",
      "r508",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r577",
      "r578",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure5WarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(5) Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r281",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r431",
      "r438",
      "r441",
      "r443",
      "r458",
      "r459",
      "r480",
      "r481",
      "r482",
      "r484",
      "r487",
      "r508",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r577",
      "r578",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r88",
      "r90",
      "r102",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r125",
      "r128",
      "r129",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r203",
      "r220",
      "r235",
      "r238",
      "r239",
      "r242",
      "r243",
      "r260",
      "r261",
      "r320",
      "r322",
      "r332",
      "r358",
      "r392",
      "r407",
      "r408",
      "r467",
      "r468",
      "r496",
      "r511",
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r274",
      "r324",
      "r330",
      "r471"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for (recovery of) losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r176"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r430",
      "r439",
      "r440",
      "r451",
      "r590"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r54",
      "r328",
      "r348",
      "r352",
      "r356",
      "r374",
      "r471"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r172",
      "r175",
      "r184",
      "r202",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r248",
      "r249",
      "r252",
      "r258",
      "r271",
      "r273",
      "r345",
      "r347",
      "r359",
      "r622"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r143",
      "r151",
      "r152",
      "r157",
      "r161",
      "r164",
      "r166",
      "r168",
      "r210",
      "r211",
      "r212",
      "r281",
      "r439",
      "r443"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(6) Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r130",
      "r213",
      "r506"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of the numerator and the denomintator used to calculate basic and diluted earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure3InventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "fil_ScheduleofglobalrevenuesbyproductcategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "ScheduleofglobalrevenuesbyproductcategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Global Revenues By Product Category",
        "documentation": "Schedule of Global Revenues by Product Category."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r166",
      "r167",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r322",
      "r323",
      "r362",
      "r363",
      "r364",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r445",
      "r458",
      "r460",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r483",
      "r490",
      "r591",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(8) Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r438",
      "r439",
      "r440",
      "r443",
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "fil_SingleOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "SingleOperatingSegmentMember",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Operating Segment",
        "documentation": "Represents the Single Operating Segment, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_StandardCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20250930",
     "localname": "StandardCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard cost of sales",
        "documentation": "Represents the monetary amount of Standard cost of sales, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r32",
      "r33",
      "r68",
      "r71",
      "r72",
      "r92",
      "r93",
      "r94",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r129",
      "r144",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r276",
      "r333",
      "r345",
      "r346",
      "r347",
      "r359",
      "r409"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r166",
      "r167",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r322",
      "r323",
      "r362",
      "r363",
      "r364",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r445",
      "r458",
      "r460",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r483",
      "r490",
      "r591",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r144",
      "r204",
      "r205",
      "r206",
      "r207",
      "r273",
      "r281",
      "r355",
      "r360",
      "r361",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r441",
      "r443",
      "r491",
      "r621"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {4}",
        "terseLabel": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {1}",
        "terseLabel": "Details",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details {3}",
        "terseLabel": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r130",
      "r213",
      "r506",
      "r507"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure6RevenueRecognitionScheduleOfGlobalRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20250930/role/idr_Disclosure8SegmentInformationScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r144",
      "r170",
      "r204",
      "r205",
      "r206",
      "r207",
      "r273",
      "r281",
      "r355",
      "r360",
      "r361",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r441",
      "r443",
      "r491",
      "r621"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54",
      "r216"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r29",
      "r32",
      "r33",
      "r54"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure4StockBasedCompensationDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r54"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r52",
      "r375",
      "r391",
      "r410",
      "r411",
      "r471",
      "r497",
      "r557",
      "r558",
      "r559",
      "r572",
      "r587",
      "r622"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r68",
      "r69",
      "r71",
      "r72",
      "r93",
      "r111",
      "r112",
      "r113",
      "r117",
      "r125",
      "r127",
      "r172",
      "r175",
      "r184",
      "r202",
      "r209",
      "r220",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r258",
      "r264",
      "r265",
      "r270",
      "r272",
      "r276",
      "r346",
      "r347",
      "r357",
      "r375",
      "r391",
      "r410",
      "r411",
      "r416",
      "r485",
      "r486",
      "r496",
      "r557",
      "r558",
      "r559",
      "r572",
      "r587",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure9SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(9) Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementsOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "verboseLabel": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20250930/role/idr_Disclosure7EarningsPerShareReconciliationOfTheNumeratorAndTheDenomintatorUsedToCalculateBasicAndDilutedEarningsPerShareDetails",
      "http://www.utahmed.com/20250930/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding - basic",
        "verboseLabel": "Weighted average shares, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r138"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>43
<FILENAME>0001096906-25-001839-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-001839-xbrl.zip
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M.MM@F.$&0])KS!OO8NE0YSS2PEBA"9+$7R>A%T:C7!C\( RH48D!CZ)$'8T
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M]%=;3"T#*X9DXHI.)?TV"-FCLYD*.A7^Z,3#:5B58M<A?.[;R9F*S7"V1A;
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MWN/@]E?2NWH<_'WP"/9DN+-(^W/?LNUM&0O*/ =P**:Y-YP]%.L< F7O@_T
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M@F;%%D/Y9,_>@H:("^(.Q>,O3X>FP3-/M=SUX;5^>6WQ-'CFG9Z@>.;2#>[
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MG2#\O?1R'PC.XJ'PHY<83S66[!N<;:AZQM#80&PBJX#8F%N)9+5U:@*MR)?
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ME$S:%_$^U!H(%06\MZVQ[GZU'"?YZC%-"??4FW(">:Z'&B0A=DVB<>\P0^5
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MGYZ(]<;B>-+8F5AS Z['LI2JAH()Y/._YN9H68V/"5V;3;Q.OM"1.G<819$
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M(F?:NI:K&E7RAV4;VD]41&=__'&^W@?=:P>^LA18NM4O8D?VZ<10MOA>\6C
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M:&)6Y5/EMRKZ)E2"#1IX<!5YNL!9ZW0)%MI:/5KKIT]:KZJ+%!:SL!'H8(2
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M)V;+81R-F/33!RO0.CII;+V+GE1EB#<H FY>6G#S3%*)MV*['=\ZQ?^[ WP
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M]Z97GY)XU^LA\ %.A9+UF:*X]3*.9M;-0[H()S9G#ZD<#UQTEN=*:%DX_;B
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MPEU Q6T* DPC%;4("I234SE<=-72][#G0:>,R"ZPC8M$R"@P"R7D1T8+K^6
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M3)8,P3!2NOURQJ$[=/2F6+V([Y3XMB0%\".U@FV]I0$P_M__$O3QN@S6;(
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M)E01/^&J)FJ+"VX'ER4 L#5+'((BE(';(X)1-DJN_6$R11UJ2A1+%-P*\LH
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M'%-]'IW RZ<OO\PVL%9@M:UK X_A(TY\* O1U*7-F'(O5CA6"_8@>S/T1#2
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MDCO!6\KT$O&T571+9OFY_J'_E\Y/;_\/4$L#!!0    ( /1Q;EMAI,_=[PH
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MTGU3+G%XNJ-$A'/[]#F]2M!H?EP(CS:-](+O'1<QZ4H)TH)!*<3[P&\XTZ$
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M:OX9I$OV"3&;];8(:HC3(D8ILPE_N9->/V9OD$LNZW]:2.(O;_\/4$L#!!0
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MGZ&5$Z-'RN ;Y*S3ARCV?R>OI1/TY>OCUZ]?H^3!(<)^@_PD6;.?3\G:LJ5
M;U\?(ZJN8_3V^,WK+_*A[)4X)!L]&W/&QGQ!Q[Q]^V4^QEXX"D\VPC4V L9+
MW[GW@^RR'7I,DH<H(-I*Z T@W4@,-LJ/0\';5DX(J"_'@_?C2V:#08/K(9K.
M)N<__C"Y'(YNIW]Q5A$![^@?=^/9ORQ#75L=5='8:3&-H'3@NO34E&2?>^<^
MP-2&M(YCOOE%^ @4C2KR0!!8T$=_<9:K;U!$3GAQ?D2DS,C1CYPF+4.?BDZJ
MB%->I-8H2[#[:A$]GGK8SP!&_K+#%?G'+Z,P)9B^\ G/=</9K'%(5]R(^$%P
MDM%$E"C*J%H""M&$"Q!(-=S;HD^73A"\7R=^B)/JI9TW"K[TC5PUK#ZCBPK"
MU@&@<=IU#/"UW?T+D\1IZ>M"_K4# _G'+UF88,H^=CA^]%V<#*.EXX>5912/
M[0H,)0F 5GI*G!V?<^J6@$-IZ@5$U+7?W=[W/H@B[X8L5K*.\544^N0YZH@*
M/?*%(C\E_\))XQ6^[=,0NUX'*2'X8>Q0P0_M&#)$E5AJ,MKU-+V6ACKE63\O
M\UL'Y99-;ETA;L9AY#Y@;TV]6",G#HE8R0V.I]0N\-Y)?)<(.?2#-0WEHR=,
M:0A91VI@1Q)L%I"=3H[?!#WDZL?V"#4T4TR'9-O$=+D8\NE//!Q&2Y]N)?+#
M-?4[I1%RG<!=!P3[Z)[*R09[F:0(YS.A&R*SU%BR)30IO>:ITH =0SY6LF#T
MK7A)SEMC\M?J,5@P$.XQY?&&8'A+%?U,Z2)&^-^VP8T[];K/4ZAWLR!A:)4!
M)!ND#1Q[/+4 PU8L[,V4BX.Z>DT[*]A[+!EL3?IROT7M"8TN#)XTNAQ<QRCC
M@'8L+ .0@C($_@;AVO1@>1D0$'L4R$.<N+&_RD_C5=-+XS"([47$%V2B+>BB
M$F%+$"*;=]GZ(E5X;U:X$3E>+L@9Z4,<?4H?:":F$VZXUKCFT7"KG% *#=:Y
M@C[*&*"<@T5(4=!#W5PG7X[NUAA",TENXFCNIU<.Y=)@<ZF/@5A6N!PA &!$
M4485960U64I XK:TAY";FTM'+W#FU*>WPX:9/2]K"%>!99N'&&*]6:6W)[X/
M.%K$SNJ!J#(8//G5&YIX+,0J+94 M"M*--'/E*HMES2EJ9>MTFK:-W),'_J)
M&T34.,=2@58X3-C^OL74,N.=1TF:%'8([!4Y1#)3&)0J]+BO:5:@S,POCK+[
MP GC@<IB6();S=JJWAET@L!XZLXX2=:T=H-2KJ?T.9UI.D+)@&X_Q@11=+ H
M.\J&?K;=_6 ]><CUH;-;A#H2Y;3(E\_,6QG/<1Q3:^_3Z(EN',P2;DHQR46D
M,L^8TH8"^&W;7EH(3@D;=(]#3,^03IK&_OTZI38NZE/HDA]PD%=N>Y757J\=
M5]@(@"<KZ@$BQ_I+3%[NM[08TF1^E^!!DN!TL(SBU/^=?0QRT3DH;DT&"N6N
M<L,,0CNR%+=9Z2CRES7!L4,9VX;>KEJJ0ABTO*:LV.12^T"8^X]X')(/(98E
M9'#&:[!@BR4!VJ]WQ%%&W3+,2>??8+)66 HC*,JX[U[4[[.O%P=#O-%0!$FD
M !X='WU:9 _-HQCYC!%*G2?K\BLD.JAB2&4IS*4VM\FOZ#&CHM\<BC+U/&<"
M,R:6(:E]EH1->1&EC(T\:EX]7Z?Z@,8,'8XLH$];1A(%.RZ6(4D^?T&^C6@Q
MC"#IP@_]%%_27-IQF!+-^^0JQ@YP";.#<_ D?0R**E6Y(-B:L/0:?TO>SM.Z
MJB:J*&NU1#TX>X>YO^G"3UPG^!=VX@ORDZ:T"]Y(B)-7PAT"FX(TRF@C2APQ
MZI8@1V'^9<>NBOI["P88>!Z-+CXG?YW$L^A34VP(;R0\"(#+74, 0$[[&%'J
M9.T1I6\10B0:J+O^Q0O0W>T_6:>)[^$[?J)%=03$Y<_A!OJ.[)/4Y.P'"-K2
MU5_A]+Q<^APUE1WZ(O@8.615@\)E_E?^>.BQ2BH)R&?ZMR-4,$"$0Q9):0E6
ME#50/4>I+889<Z:3/-#_T^OGHQ-@ED%-;@Z^2QVRY!>L'$[Y!Z61/),GB";8
M+*IC1J#[)2&)G!3=XX4?TG6FEOOL+:>QIJ&Q::XJ1>'_O\RXJ-XOF"\./:69
M'L0ZKD-;-0NZMIUMR&E.#B6N[S0$B#<.@;N]Z_Q U\(2/<O@U335NC^:H]M#
M5I+>>ABAE:1%A'JJ)*T@.^C#5:DD/;D9W0YFS[&2M(*B%"M)JZZRV2RZR9S*
M>A%$GV3@%3ZB+<-.( _L_9<Z?I"@/[[060U:E]3"\L^YZ)9M%Y6I<],&90@Z
MR+TW3X)6O/46HW7?>2M2@$Q]Y3SW(LR2\D O\U3X(XU[0<-$'G%\'_$W FP^
M-ESG*SJ17>:;,&8VPBX/39!]&OCCM<7,\20!F48+X@AGU"V#CW3RW)@WX3J8
M*8[(?'D2W%0&@0L@-O($A4].IZ.9;2?5YFG6JACR==MG(O5%X"P:O&3[O]>2
M.EWFI"=GFE*T9*VY,VW,DJXIM3>/* U:BU=1S&[B[#QW3FMEQIOSR*NNF.I3
M<$^IDE0:O*9[?(X1XT2=ISDW1-E9!* 6RJD[5-77#.!<)6\G3$U\ N]J=0C(
MO<KA!SI$;&GJ<JT"A&SK6]VR>F9N58Z*]ORJ(N 8[>\XBP;N;VL_QM5()\ZI
M2/Z<KNZ.4LD@&V/<(G3M,!-0:^/89AX'R4U4U06O::,:SLR:);,89IIF$854
MQH92 VK/:#-,BB0"'2T87;0C;%?]@59ZX!K\I$MSH$0'+J1J _4G-N@ #VL#
MGB6CMDQK,"M_NFU7KG42=N1F\-$O1)'1'A7D74_3F-6Z4U0&Z^I+T2P#Z.I>
M=*189:0M@XIXXKRV$P+MFZI4T=QT\QH+NLKR']%0GT(J#S"_L*&]JHW-3%0T
MT5" 0FUI>DRRF!&*#;:AO5_K2*<H\]&20T$)6H(!WCR;<B5J"C5SNEJO5@$[
M[3E!X=X=A_,H7C)KA"RZ0/%I\#FLG92@;-.[FYO+T=7H>C:X1,/Q]/QR,KV[
M':')!=K&QZ#Q]<7D]FHP&T^N+4%:1TW53C\=%O20T5SC\!$G.J*Y1(1ZBN92
MD%UG--?X^J?1]%E&<RDH2C&:2W65S9SRO?]>)VENS"GZ)M"N95F-@<LH(3]7
MC$GCW0UTL@#?*'J8+_P:[NRDTGCQ/M1<%:[L:A,^R,VK!Z75[FM][0CC'>*S
MJNL-SC<8O0-TB]^?">B;!^Z#+NT!;*4^6GH0=:D)O0Q9JT4V@/WDZ'FY)+4L
MD(9^\@U[S\@1Y): @JB*INT,\2,.(F9D$%?@$S\#/20H201Y110,\GZXWHZ)
M);ALI8GJYTU]<0P5RTO2R?Q#%'GE?HO3*.!W?.$^ "^7)Y,%]N5)6(7&!:6/
M$D+5,CC)IU\OEZ>T%@8#4R6.D+TQ>L)2-;H]LM.WFQ>?TAY<T5E>A2N#LM"'
M"ZR5N6FXV.C!@D[+F0QB['"B*_=^#;&@-_$!O<-8C1E"T+:0R*:)EDWH7(WV
M%E$[<Y[&'H&2/Z<'7'*$DS1^YXV'1]%*)-$0/TNK:^^SL+5!O$07]7!9E67I
MT<5V4Q0:&))+DL#7MC].A].MD;,6[UM&&1'2B-*V""/"N3=YY/AJ-Y//16L)
MCL,4DS5-6;]7:I *O<Q2Q3D$21X"9W8IR02*S&85% L6S"A1,+&S#+6:2FI)
M7^KK9%FUA'9^M3X<">UEA0"2<$,N+?BRROFA^PV*MDF(SI:9QL-\/S,4GO1U
M3-,BGV$+ET!'Y)JJ$Q_33@A#G/TY#BL!9YS=*'].0^UX-<ETA@JB/\YT5H+0
M.@=A.0C+8QZ5%=%0#K\%S@Z\93*+/)6*?'#9!WBWQT6I/1"*_6TSY=EHV8#Q
MEAL[DD7LE+;[H<Z/7]]35DL@TC%SN[:RLO;4-WD[_)L):&2N-%J?-27+103A
M;.KZ.'"0(H^SAD2C]TY F]!I]$]KD5JA-N1SF("@U&-K\0\2],E302V\4PAZ
M<U:-ZRC<7BVR&Z^DZYOX(2U6#:E,<*N&;ZW]0CKY1ON%VHH8=! */8.:7(+Z
M?($]^0 U._\L=OJ)O7T']E(K55'2W3E)* '(-_AL7,!J)98.WB6)O4"G." T
M%Q]P2-ZB 3E##[RE'_I4IM1_5/DH*E+0\H5L)RW\<YGS.T8Y1W;_VN>)1G;6
M@&NOKL8/;(?5-5HD93(O_!:RLBCED;H*H31P!Z649F1I%)=7T.VA^DE;J=7,
M%2V%/V3)DP8%\(J<\%!CSI+PWDFP1TM@D(TFJB//&:S%IL"5 93G2,./3^XI
M:5J6=4O;TJJ:8D4TWG/%JV&N=LDM7I%5?J#2[&+!ARQ*/HLP:,SDZ$1"2[V3
MEO)JR]?8<BUG(MAJ<>F@J,9*(UU6UAQTQTFRWA?G)R=8XW+J0I'0P(OH;D]'
M"XB[2*X-R3YC7D^BP<M5$&TPWL^FL1':7=37B._.*V\$Y!^QOW@@IZK!(SE?
M+W 6_4</':R$MZHKH2T5*, [2@TZ+63Y7M&.*CI!>?UVR_#;43M5]$(6]2"=
M$,AQQW<Y"&T>J[L+PIX$(*=7N6< ^_X?HWM*O,?.!ZV%;]/W0'$.A]@N0CW(
M>AW4<62HK]<<Q^2<-'.>2HW/::;2)S^@9I)J34S%&JYPNO .8IIF!HKESH5
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MA%^__ZSX"?D/.7/A[S_[7U!+ P04    " #T<6Y;]CD(0%,9  !4EP$ %0
M '5T;60M,C R-3 Y,S!?<')E+GAM;.U=6W/;N))^GOD5WNQ#=JO&L9U,)I>:
MS"GY6JYQ8J_M3,[NUM8414(23BA  Y"R-+]^ 5XDWAH$)8H$;%>=,TGL!MC]
M=:/1#32 7_^QF/I[<\0XIN33RZ-7AR_W$'&IA\GXTTO,Z?[[]V\_[!^]_,=O
M/_[Z;_O[>S>,>J&+O+WA<N_L]&)PRT,<H#U.1\&#P]!/>P-O[A!)<$*GLS!
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M7M=G:5:,7H_.,1&,8,$HC1>?:X[7:#7=:KQO(M" <X%C#>L%HG['>Q,52!<
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M.LI95:4RJB4V2#>9"O?/J.*!5)C.$!VH; HHY4\%-4@-P&EYI4K4;2Q33PT
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M.[/1UI1]UV;\!8F. \<'L2X0F UJ49KV/&XU>B(@I]%M:#)E^TQ%GD:9?!^
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M,#(U,#DS,"YX<V102P$"% ,4    " #T<6Y;W1T".F.X  !)[P@ %0
M        @ 'U"   =71M9"TR,#(U,#DS,%\Q,'$N:'1M4$L! A0#%     @
M]'%N6Z*LE9XT"0  HW4  !4              ( !B\$  '5T;60M,C R-3 Y
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( /1Q;EMAI,_=[PH  ,&(   5
M      "  ?+*  !U=&UD+3(P,C4P.3,P7V1E9BYX;6Q02P$"% ,4    " #T
M<6Y;FTE@GE$H  #@\@$ %0              @ $4U@  =71M9"TR,#(U,#DS
M,%]L86(N>&UL4$L! A0#%     @ ]'%N6_8Y"$!3&0  5)<! !4
M     ( !F/X  '5T;60M,C R-3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( /1Q
M;EN,/,3-^08  ,P;   /              "  1X8 0!U=&UD7V5X,S%Z,2YH
M=&U02P$"% ,4    " #T<6Y;#LQDF@,'  #;&P  #P              @ %$
M'P$ =71M9%]E>#,Q>C(N:'1M4$L! A0#%     @ ]'%N6]NC<M-H!   R0P
M  \              ( !="8! '5T;61?97@S,GHQ+FAT;5!+ 0(4 Q0    (
M /1Q;EOLIZ-95@0  "\-   /              "  0DK 0!U=&UD7V5X,S)Z
;,BYH=&U02P4&      H "@"" @  C"\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>utmd-20250930_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:fil="http://www.utahmed.com/20250930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250930.xsd" xlink:type="simple"/>
    <context id="D250101_250930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="E25Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="E24Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I251110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-11-10</instant>
        </period>
    </context>
    <context id="E24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Y25Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y24Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D240101_240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="E23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E24Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D250101_250930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="E25Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="E25Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="Y25Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="E25Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="E25Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="E25Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="E25Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="E24_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="E24Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Y24Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Y24Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Y24Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Y24Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="E24Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="E24Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="E24Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="E24Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="E23_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D240101_240930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D240101_240930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D240101_240930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D240101_240930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y25Q3_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Y24Q3_StScenario-SingleOperatingSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">fil:SingleOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D250101_250930" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D250101_250930" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="D250101_250930" id="fact3">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D250101_250930" id="fact4">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D250101_250930" id="fact5">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D250101_250930" id="ixv-6827">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D250101_250930" id="ixv-6828">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D250101_250930" id="ixv-6829">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D250101_250930" id="ixv-6830">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D250101_250930" id="ixv-6831">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D250101_250930" id="ixv-6832">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D250101_250930" id="ixv-6833">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D250101_250930" id="ixv-6834">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D250101_250930" id="ixv-6835">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D250101_250930" id="ixv-6836">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D250101_250930" id="ixv-6837">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D250101_250930" id="ixv-6838">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D250101_250930" id="ixv-6839">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D250101_250930" id="ixv-6840">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D250101_250930" id="ixv-6841">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D250101_250930" id="ixv-6842">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D250101_250930" id="ixv-6843">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="D250101_250930" id="ixv-6844">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="D250101_250930" id="ixv-6845">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D250101_250930" id="ixv-6846">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D250101_250930" id="ixv-6847">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D250101_250930" id="ixv-6848">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D250101_250930" id="ixv-6849">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I251110"
      decimals="INF"
      id="ixv-6850"
      unitRef="Shares">3203672</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6851"
      unitRef="USD">84267000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E24" decimals="-3" id="ixv-6852" unitRef="USD">82976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6853"
      unitRef="USD">3725000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E24" decimals="-3" id="ixv-6854" unitRef="USD">4094000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6855"
      unitRef="USD">8118000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-6856" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6857"
      unitRef="USD">422000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E24" decimals="-3" id="ixv-6858" unitRef="USD">448000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6859"
      unitRef="USD">96532000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E24" decimals="-3" id="ixv-6860" unitRef="USD">96330000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6861"
      unitRef="USD">10000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E24" decimals="-3" id="ixv-6862" unitRef="USD">9763000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6863"
      unitRef="USD">14051000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E24" decimals="-3" id="ixv-6864" unitRef="USD">13580000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6865"
      unitRef="USD">55948000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E24" decimals="-3" id="ixv-6866" unitRef="USD">53772000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6867"
      unitRef="USD">54556000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E24" decimals="-3" id="ixv-6868" unitRef="USD">50907000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6869"
      unitRef="USD">1392000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E24" decimals="-3" id="ixv-6870" unitRef="USD">2865000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6871"
      unitRef="USD">121975000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E24" decimals="-3" id="ixv-6872" unitRef="USD">122538000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6873"
      unitRef="USD">768000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E24" decimals="-3" id="ixv-6874" unitRef="USD">696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6875"
      unitRef="USD">2243000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-6876" unitRef="USD">3061000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6877"
      unitRef="USD">3011000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E24" decimals="-3" id="ixv-6878" unitRef="USD">3757000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6879"
      unitRef="USD">248000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E24" decimals="-3" id="ixv-6880" unitRef="USD">603000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6881"
      unitRef="USD">241000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="E24" decimals="-3" id="ixv-6882" unitRef="USD">282000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6883"
      unitRef="USD">223000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E24" decimals="-3" id="ixv-6884" unitRef="USD">469000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6885"
      unitRef="USD">3723000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E24" decimals="-3" id="ixv-6886" unitRef="USD">5111000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E25Q3"
      decimals="INF"
      id="ixv-6887"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E24"
      decimals="INF"
      id="ixv-6888"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6889"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E24"
      decimals="-3"
      id="ixv-6890"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6891"
      unitRef="Shares">3204000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6892"
      unitRef="Shares">3204000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="E24"
      decimals="-3"
      id="ixv-6893"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E24"
      decimals="-3"
      id="ixv-6894"
      unitRef="Shares">3335000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6895"
      unitRef="USD">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E24" decimals="-3" id="ixv-6896" unitRef="USD">33000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6897"
      unitRef="USD">-9738000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E24" decimals="-3" id="ixv-6898" unitRef="USD">-11908000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6899"
      unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E24" decimals="-3" id="ixv-6900" unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6901"
      unitRef="USD">127958000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E24" decimals="-3" id="ixv-6902" unitRef="USD">129302000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6903"
      unitRef="USD">118252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E24" decimals="-3" id="ixv-6904" unitRef="USD">117427000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-6905"
      unitRef="USD">121975000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E24" decimals="-3" id="ixv-6906" unitRef="USD">122538000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6907"
      unitRef="USD">9812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6908"
      unitRef="USD">10005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6909"
      unitRef="USD">29475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6910"
      unitRef="USD">31745000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6911"
      unitRef="USD">4208000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6912"
      unitRef="USD">4203000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6913"
      unitRef="USD">12738000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6914"
      unitRef="USD">12925000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6915"
      unitRef="USD">5604000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6916"
      unitRef="USD">5802000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6917"
      unitRef="USD">16737000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6918"
      unitRef="USD">18820000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6919"
      unitRef="USD">2826000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6920"
      unitRef="USD">2287000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6921"
      unitRef="USD">7320000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6922"
      unitRef="USD">7464000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6923"
      unitRef="USD">167000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6924"
      unitRef="USD">172000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6925"
      unitRef="USD">456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6926"
      unitRef="USD">692000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6927"
      unitRef="USD">2993000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6928"
      unitRef="USD">2459000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6929"
      unitRef="USD">7776000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6930"
      unitRef="USD">8156000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6931"
      unitRef="USD">2611000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6932"
      unitRef="USD">3343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6933"
      unitRef="USD">8961000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6934"
      unitRef="USD">10664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6935"
      unitRef="USD">698000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6936"
      unitRef="USD">836000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6937"
      unitRef="USD">2043000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6938"
      unitRef="USD">2524000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6939"
      unitRef="USD">3309000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6940"
      unitRef="USD">4179000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6941"
      unitRef="USD">11004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6942"
      unitRef="USD">13188000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6943"
      unitRef="USD">678000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6944"
      unitRef="USD">616000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6945"
      unitRef="USD">2284000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6946"
      unitRef="USD">2216000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6947"
      unitRef="USD">2631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6948"
      unitRef="USD">3563000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6949"
      unitRef="USD">8720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6950"
      unitRef="USD">10972000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q3"
      decimals="INF"
      id="ixv-6951"
      unitRef="UsdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q3"
      decimals="INF"
      id="ixv-6952"
      unitRef="UsdPerShare">1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D250101_250930"
      decimals="INF"
      id="ixv-6953"
      unitRef="UsdPerShare">2.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240930"
      decimals="INF"
      id="ixv-6954"
      unitRef="UsdPerShare">3.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q3"
      decimals="INF"
      id="ixv-6955"
      unitRef="UsdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q3"
      decimals="INF"
      id="ixv-6956"
      unitRef="UsdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D250101_250930"
      decimals="INF"
      id="ixv-6957"
      unitRef="UsdPerShare">2.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240930"
      decimals="INF"
      id="ixv-6958"
      unitRef="UsdPerShare">3.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6959"
      unitRef="Shares">3207000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6960"
      unitRef="Shares">3478000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6961"
      unitRef="Shares">3254000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6962"
      unitRef="Shares">3542000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6963"
      unitRef="Shares">3207000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6964"
      unitRef="Shares">3478000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6965"
      unitRef="Shares">3254000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6966"
      unitRef="Shares">3542000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y25Q3"
      decimals="INF"
      id="ixv-6967"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q3"
      decimals="INF"
      id="ixv-6968"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D250101_250930"
      decimals="INF"
      id="ixv-6969"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="D240101_240930"
      decimals="INF"
      id="ixv-6970"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6971"
      unitRef="USD">-376000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6972"
      unitRef="USD">1432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6973"
      unitRef="USD">2170000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6974"
      unitRef="USD">769000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-6975"
      unitRef="USD">2255000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-6976"
      unitRef="USD">4995000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6977"
      unitRef="USD">10890000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6978"
      unitRef="USD">11741000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6979"
      unitRef="USD">8720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6980"
      unitRef="USD">10972000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6981"
      unitRef="USD">614000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6982"
      unitRef="USD">530000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6983"
      unitRef="USD">1593000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6984"
      unitRef="USD">1548000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6985"
      unitRef="USD">395000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6986"
      unitRef="USD">-6000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6987"
      unitRef="USD">41000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6988"
      unitRef="USD">38000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6989"
      unitRef="USD">-641000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6990"
      unitRef="USD">-417000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6991"
      unitRef="USD">262000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6992"
      unitRef="USD">184000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6993"
      unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6994"
      unitRef="USD">20000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6995"
      unitRef="USD">97000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6996"
      unitRef="USD">306000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6997"
      unitRef="USD">-1009000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-6998"
      unitRef="USD">-508000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-6999"
      unitRef="USD">-52000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7000"
      unitRef="USD">-54000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7001"
      unitRef="USD">69000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7002"
      unitRef="USD">229000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7003"
      unitRef="USD">-802000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7004"
      unitRef="USD">-1460000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7005"
      unitRef="USD">2495000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7006"
      unitRef="USD">922000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7007"
      unitRef="USD">11215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7008"
      unitRef="USD">11894000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7009"
      unitRef="USD">262000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7010"
      unitRef="USD">221000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7011"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7012"
      unitRef="USD">5000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7013"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7014"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7015"
      unitRef="USD">-262000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7016"
      unitRef="USD">-199000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7017"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7018"
      unitRef="USD">390000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7019"
      unitRef="USD">7361000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7020"
      unitRef="USD">13259000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7021"
      unitRef="USD">3006000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7022"
      unitRef="USD">3222000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7023"
      unitRef="USD">-10367000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7024"
      unitRef="USD">-16091000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7025"
      unitRef="USD">705000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7026"
      unitRef="USD">-20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7027"
      unitRef="USD">1291000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7028"
      unitRef="USD">-4416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E24" decimals="-3" id="ixv-7029" unitRef="USD">82976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23" decimals="-3" id="ixv-7030" unitRef="USD">92868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7031"
      unitRef="USD">84267000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E24Q3"
      decimals="-3"
      id="ixv-7032"
      unitRef="USD">88452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7033"
      unitRef="USD">2852000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7034"
      unitRef="USD">3713000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7035"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7036"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="E25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7037"
      unitRef="Shares">3216000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7038"
      unitRef="USD">32000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7039"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7040"
      unitRef="USD">-9362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7041"
      unitRef="USD">126862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q2"
      decimals="-3"
      id="ixv-7042"
      unitRef="USD">117533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7043"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7044"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7045"
      unitRef="USD">95000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7046"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7047"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7048"
      unitRef="USD">95000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7049"
      unitRef="Shares">-12000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7050"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7051"
      unitRef="USD">-95000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7052"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7053"
      unitRef="USD">-558000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7054"
      unitRef="USD">-653000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7055"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7056"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7057"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7058"
      unitRef="USD">-376000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7059"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7060"
      unitRef="USD">-376000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7061"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7062"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7063"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7064"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7065"
      unitRef="USD">977000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7066"
      unitRef="USD">977000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7067"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7068"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7069"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7070"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7071"
      unitRef="USD">2631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7072"
      unitRef="USD">2631000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7073"
      unitRef="Shares">3204000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7074"
      unitRef="USD">32000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7075"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7076"
      unitRef="USD">-9738000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7077"
      unitRef="USD">127958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7078"
      unitRef="USD">118252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7079"
      unitRef="Shares">3335000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7080"
      unitRef="USD">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7081"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7082"
      unitRef="USD">-11908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7083"
      unitRef="USD">129302000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E24" decimals="-3" id="ixv-7084" unitRef="USD">117427000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7085"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7086"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7087"
      unitRef="USD">262000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7088"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7089"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7090"
      unitRef="USD">262000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7091"
      unitRef="Shares">-131000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7092"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D250101_250930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7093"
      unitRef="USD">-262000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D250101_250930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7094"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D250101_250930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7095"
      unitRef="USD">-7098000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7096"
      unitRef="USD">-7361000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7097"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7098"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7099"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7100"
      unitRef="USD">2170000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7101"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7102"
      unitRef="USD">2170000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7103"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7104"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7105"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7106"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7107"
      unitRef="USD">2966000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7108"
      unitRef="USD">2966000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7109"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7110"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7111"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7112"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7113"
      unitRef="USD">8720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7114"
      unitRef="USD">8720000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7115"
      unitRef="Shares">3204000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7116"
      unitRef="USD">32000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7117"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7118"
      unitRef="USD">-9738000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7119"
      unitRef="USD">127958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7120"
      unitRef="USD">118252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7121"
      unitRef="Shares">3499000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7122"
      unitRef="USD">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7123"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7124"
      unitRef="USD">-11322000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7125"
      unitRef="USD">135339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q2"
      decimals="-3"
      id="ixv-7126"
      unitRef="USD">124052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7127"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7128"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7129"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7130"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7131"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7132"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7133"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7134"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7135"
      unitRef="USD">53000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7136"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7137"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7138"
      unitRef="USD">53000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7139"
      unitRef="Shares">-58000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7140"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7141"
      unitRef="USD">-53000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7142"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7143"
      unitRef="USD">-3812000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7144"
      unitRef="USD">-3866000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7145"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7146"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7147"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7148"
      unitRef="USD">1432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7149"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7150"
      unitRef="USD">1432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7151"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7152"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7153"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7154"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7155"
      unitRef="USD">1038000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7156"
      unitRef="USD">1038000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7157"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7158"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7159"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7160"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7161"
      unitRef="USD">3563000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7162"
      unitRef="USD">3563000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7163"
      unitRef="Shares">3441000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7164"
      unitRef="USD">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7165"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7166"
      unitRef="USD">-9890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7167"
      unitRef="USD">134053000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3"
      decimals="-3"
      id="ixv-7168"
      unitRef="USD">124197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7169"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7170"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7171"
      unitRef="USD">593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7172"
      unitRef="USD">-10658000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E23_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7173"
      unitRef="USD">138341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E23" decimals="-3" id="ixv-7174" unitRef="USD">128313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7175"
      unitRef="Shares">8000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7176"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7177"
      unitRef="USD">390000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7178"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7179"
      unitRef="USD">0</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7180"
      unitRef="USD">390000</fil:CommonStockReceivedAndRetiredUponExerciseOfStockOptions>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7181"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7182"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7183"
      unitRef="USD">184000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7184"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7185"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7186"
      unitRef="USD">184000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7187"
      unitRef="Shares">-197000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7188"
      unitRef="USD">-2000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7189"
      unitRef="USD">-1168000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7190"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7191"
      unitRef="USD">-12090000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7192"
      unitRef="USD">-13259000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7193"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7194"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7195"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7196"
      unitRef="USD">769000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7197"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7198"
      unitRef="USD">769000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7199"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7200"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7201"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7202"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7203"
      unitRef="USD">3171000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7204"
      unitRef="USD">3171000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7205"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7206"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7207"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7208"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7209"
      unitRef="USD">10972000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7210"
      unitRef="USD">10972000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7211"
      unitRef="Shares">3441000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-7212"
      unitRef="USD">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-7213"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-7214"
      unitRef="USD">-9890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-7215"
      unitRef="USD">134053000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E24Q3"
      decimals="-3"
      id="ixv-7216"
      unitRef="USD">124197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D250101_250930" id="ixv-3673">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(1)&lt;/kbd&gt;&lt;kbd style="margin-left:19.8pt"&gt;&lt;/kbd&gt;The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2024. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&#160;&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D250101_250930" id="ixv-3678">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:6pt"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. &#160;ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting AUS 2023-09.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. &#160;ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. &#160;The Company is currently evaluating the impact of adopting ASU 2024-03.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D250101_250930" id="ixv-3685">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(3)&lt;/kbd&gt;&lt;kbd style="margin-left:19.8pt"&gt;&lt;/kbd&gt;Inventories at September 30, 2025, and December 31, 2024, consisted of the following:&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2025&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:97.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;1,224&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:93.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;1,913&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;1,606&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;1,414&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;5,288&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;5,485&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;8,118&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;8,812&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D250101_250930" id="ixv-3689">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2025&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:97.35pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;1,224&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:93.6pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;1,913&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;1,606&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;1,414&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:97.35pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;5,288&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:93.6pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;5,485&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:141.6pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:60.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:97.35pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:80pt"&gt;8,118&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:11.8pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:93.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:7pt"&gt;$&lt;/kbd&gt;&lt;kbd style="position:absolute;text-align:right;font:10pt Times New Roman;width:77pt"&gt;8,812&lt;/kbd&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7217"
      unitRef="USD">1224000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E24" decimals="-3" id="ixv-7218" unitRef="USD">1913000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7219"
      unitRef="USD">1606000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E24" decimals="-3" id="ixv-7220" unitRef="USD">1414000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7221"
      unitRef="USD">5288000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E24" decimals="-3" id="ixv-7222" unitRef="USD">5485000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="E25Q3"
      decimals="-3"
      id="ixv-7223"
      unitRef="USD">8118000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E24" decimals="-3" id="ixv-7224" unitRef="USD">8812000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D250101_250930" id="ixv-3774">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(4)&lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Stock-Based Compensation. At September 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2025, and 2024, the Company recognized $95 and $53, respectively, in stock-based compensation cost. &#160;In the nine months ended September 30, 2025, and 2024, the Company recognized $262 and $184, respectively, in stock-based compensation cost.&#160;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7227"
      unitRef="USD">95000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7228"
      unitRef="USD">53000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7229"
      unitRef="USD">262000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7230"
      unitRef="USD">184000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D250101_250930" id="ixv-3780">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"&gt;(5) &lt;/kbd&gt;&lt;kbd style="margin-left:18pt"&gt;&lt;/kbd&gt;Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024, or September 30, 2025. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D250101_250930" id="ixv-3790">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) Global 3Q 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;869&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;170&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;1,039&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,521&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;2,433&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;4,954&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;554&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;2,176&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Blood Pressure Monitoring and Accessorie&lt;/span&gt;s*&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;847&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;796&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;1,643&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"&gt;&lt;span style="color:#000000"&gt;Total:&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;5,859&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;3,953&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;9,812&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,519&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;570&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;3,089&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;7,272&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;7,384&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;14,656&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;4,981&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;1,280&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;6,261&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Blood Pressure Monitoring and Accessories*&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,536&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;2,933&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;5,469&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"&gt;&lt;span style="color:#000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;17,308&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;12,167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;29,475&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;*includes assemblies and molded components sold to OEM customers. &lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock contextRef="D250101_250930" id="ixv-3792">&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;869&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;170&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;1,039&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,521&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;2,433&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;4,954&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;554&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;2,176&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Blood Pressure Monitoring and Accessorie&lt;/span&gt;s*&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;847&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;796&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;1,643&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"&gt;&lt;span style="color:#000000"&gt;Total:&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;5,859&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:5.25pt;text-align:right"&gt;3,953&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;9,812&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2025 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Domestic&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Outside US&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Labor &amp;amp; Delivery&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,519&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;570&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;3,089&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;7,272&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;7,384&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;14,656&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;4,981&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;1,280&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;6,261&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;Blood Pressure Monitoring and Accessories*&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;2,536&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;2,933&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:43.85pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;5,469&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#D3F0FE;width:184.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt;color:#339966;text-align:right"&gt;&lt;span style="color:#000000"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;:&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:4.5pt;text-align:right"&gt;17,308&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-left:-5.25pt;margin-right:5.25pt;text-align:right"&gt;12,167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:43.85pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;margin-right:2.5pt;text-align:right"&gt;29,475&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</fil:ScheduleofglobalrevenuesbyproductcategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7231"
      unitRef="USD">869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7232"
      unitRef="USD">170000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-7233"
      unitRef="USD">1039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7234"
      unitRef="USD">2521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7235"
      unitRef="USD">2433000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-7236"
      unitRef="USD">4954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7237"
      unitRef="USD">1622000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7238"
      unitRef="USD">554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-7239"
      unitRef="USD">2176000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7240"
      unitRef="USD">847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7241"
      unitRef="USD">796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-7242"
      unitRef="USD">1643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7243"
      unitRef="USD">5859000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7244"
      unitRef="USD">3953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7245"
      unitRef="USD">9812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7246"
      unitRef="USD">2519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7247"
      unitRef="USD">570000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-7248"
      unitRef="USD">3089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7249"
      unitRef="USD">7272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7250"
      unitRef="USD">7384000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-7251"
      unitRef="USD">14656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7252"
      unitRef="USD">4981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7253"
      unitRef="USD">1280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-7254"
      unitRef="USD">6261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7255"
      unitRef="USD">2536000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7256"
      unitRef="USD">2933000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-7257"
      unitRef="USD">5469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-7258"
      unitRef="USD">17308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-7259"
      unitRef="USD">12167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7260"
      unitRef="USD">29475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="D250101_250930" id="ixv-4071">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3&lt;span style="vertical-align:super"&gt;rd&lt;/span&gt; quarter 2025.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,631&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,563&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,720&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,972&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,207&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,478&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,254&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,542&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,207&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,478&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,254&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,542&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.82&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.68&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.82&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.68&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D250101_250930" id="ixv-4076">&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:131.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:153pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2025&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;2024&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,631&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,563&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,720&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,972&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,207&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,478&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,254&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,542&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,207&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,478&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,254&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,542&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.82&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.68&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#D3F0FE;width:149.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:53.45pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.82&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:15.3pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:63pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:18pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:72pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.68&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:13.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;width:67.5pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3.10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7262"
      unitRef="USD">2631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7263"
      unitRef="USD">3563000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7264"
      unitRef="USD">8720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7265"
      unitRef="USD">10972000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7266"
      unitRef="Shares">3207000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7267"
      unitRef="Shares">3478000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7268"
      unitRef="Shares">3254000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7269"
      unitRef="Shares">3542000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7270"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7271"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7272"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7273"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y25Q3"
      decimals="-3"
      id="ixv-7274"
      unitRef="Shares">3207000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q3"
      decimals="-3"
      id="ixv-7275"
      unitRef="Shares">3478000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D250101_250930"
      decimals="-3"
      id="ixv-7276"
      unitRef="Shares">3254000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D240101_240930"
      decimals="-3"
      id="ixv-7277"
      unitRef="Shares">3542000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y25Q3"
      decimals="INF"
      id="ixv-7278"
      unitRef="UsdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q3"
      decimals="INF"
      id="ixv-7279"
      unitRef="UsdPerShare">1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D250101_250930"
      decimals="INF"
      id="ixv-7280"
      unitRef="UsdPerShare">2.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D240101_240930"
      decimals="INF"
      id="ixv-7281"
      unitRef="UsdPerShare">3.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y25Q3"
      decimals="INF"
      id="ixv-7282"
      unitRef="UsdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q3"
      decimals="INF"
      id="ixv-7283"
      unitRef="UsdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D250101_250930"
      decimals="INF"
      id="ixv-7284"
      unitRef="UsdPerShare">2.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D240101_240930"
      decimals="INF"
      id="ixv-7285"
      unitRef="UsdPerShare">3.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="D250101_250930" id="ixv-4294">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Segment Information. &#160;The Company operates as one operating segment. &#160;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its chief executive officer, who reviews financial information presented on a consolidated basis. &#160;The CODM uses consolidated gross profit margin, operating margin, and net income to assess financial performance and allocate resources. &#160;These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;The following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the quarters ended September 30, 2025 and September 30, 2024:&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;Quarter Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,812&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,005&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,359&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,456&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;849&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;747&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,604&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,802&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;57.1%&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;58.0%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;516&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;437&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;171&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;384&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;426&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;544&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;525&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,382&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;900&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,611&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,343&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;26.6%&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;33.4%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;719&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;872&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(21)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(36)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,309&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,179&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;678&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;615&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,631&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,564&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="D250101_250930" id="ixv-4304">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse"&gt;&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;Quarter Ended September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,812&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,005&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Less:&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Standard cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,359&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,456&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other cost of sales&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;849&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;747&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,604&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,802&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gross Profit Margin&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;57.1%&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;58.0%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Sales &amp;amp; Marketing&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;516&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;437&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Research &amp;amp; Development&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;167&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;171&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Litigation Fees&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;384&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;426&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Amortization&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;544&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;525&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other General &amp;amp; Administrative&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,382&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;900&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,611&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,343&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Income Margin&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;26.6%&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;33.4%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Interest income&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;719&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;872&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other income (expense)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(21)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(36)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Income before income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,309&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,179&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Provision for income taxes&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;678&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#D3F0FE;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;615&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:7.2pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net Income&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,631&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,564&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7288"
      unitRef="USD">9812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7289"
      unitRef="USD">10005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fil:StandardCostOfSales
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7290"
      unitRef="USD">3359000</fil:StandardCostOfSales>
    <fil:StandardCostOfSales
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7291"
      unitRef="USD">3456000</fil:StandardCostOfSales>
    <fil:OtherCostOfSales
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7292"
      unitRef="USD">849000</fil:OtherCostOfSales>
    <fil:OtherCostOfSales
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7293"
      unitRef="USD">747000</fil:OtherCostOfSales>
    <us-gaap:GrossProfit
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7294"
      unitRef="USD">5604000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7295"
      unitRef="USD">5802000</us-gaap:GrossProfit>
    <fil:GrossProfitMargin
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7296"
      unitRef="Pure">0.571</fil:GrossProfitMargin>
    <fil:GrossProfitMargin
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7297"
      unitRef="Pure">0.58</fil:GrossProfitMargin>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7298"
      unitRef="USD">516000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7299"
      unitRef="USD">437000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7300"
      unitRef="USD">167000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7301"
      unitRef="USD">171000</us-gaap:ResearchAndDevelopmentExpense>
    <fil:LitigationExpense
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7302"
      unitRef="USD">384000</fil:LitigationExpense>
    <fil:LitigationExpense
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7303"
      unitRef="USD">426000</fil:LitigationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7304"
      unitRef="USD">544000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7305"
      unitRef="USD">525000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7306"
      unitRef="USD">1382000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7307"
      unitRef="USD">900000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7308"
      unitRef="USD">2611000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7309"
      unitRef="USD">3343000</us-gaap:OperatingIncomeLoss>
    <fil:OperatingIncomeMargin
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7310"
      unitRef="Pure">0.266</fil:OperatingIncomeMargin>
    <fil:OperatingIncomeMargin
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="INF"
      id="ixv-7311"
      unitRef="Pure">0.334</fil:OperatingIncomeMargin>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7312"
      unitRef="USD">719000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7313"
      unitRef="USD">872000</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7314"
      unitRef="USD">-21000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7315"
      unitRef="USD">-36000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7316"
      unitRef="USD">3309000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7317"
      unitRef="USD">4179000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7318"
      unitRef="USD">678000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7319"
      unitRef="USD">615000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y25Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7320"
      unitRef="USD">2631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q3_StScenario-SingleOperatingSeg"
      decimals="-3"
      id="ixv-7321"
      unitRef="USD">3564000</us-gaap:ProfitLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="D250101_250930" id="ixv-4508">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements. After September 30, 2025 through November 10, 2025, the Company made additional repurchases of 500 shares of its stock in the open market for $29, at a price of $57.90 per share.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
